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ABSTRACT 
 
Delman, Emily. M.S., Department of Biochemistry and Molecular Biology, Wright 
State University, 2016.  Effects of Synthetic Ligands on Heterodimer Pairs Regarding 
Full-Length Human PPARα, RXRα and LXRα. 
 
 Nuclear receptor study is critically relevant in therapeutic medicine since the 
intricate details of disease states pertaining to atherosclerosis and diabetes are poorly 
understood.  Three nuclear receptors of interest regulate target genes pertaining to 
cholesterol and fatty acid regulation, linking these receptors to therapeutic medicine.  
The first is the peroxisome proliferator-activated receptor alpha (PPARα), which 
resides in liver and muscle, coordinating lipoprotein and fatty acid homeostasis [1].  
Cholesterol homeostasis is dictated by the liver X receptor alpha (LXRα), targeting 
genes pertaining to the kidney, intestine, liver and adipose tissues [2].  A common 
partner receptor to PPARα and LXRα is known as the retinoid X receptor alpha 
(RXRα) [3].  Although each receptor appears unique in function, the cause and effects 
of disease states are poorly understood due to the promiscuous nature of these 
receptor proteins.  These particular receptors can form permissive heterodimers where 
metabolic effects can be manipulated by ligands [3].  Accordingly, clinical care 
becomes increasingly complex as synthetic ligands made to target one receptor could 
have additional repercussions.  With respect to therapeutic medicine, ligand binding 
may not be exclusive.  Therefore, it becomes necessary to study synthetic ligands 
with each receptor, individually and in heterodimeric form, to further understand the 
complex regulation and clinical implications of synthetic ligands on disease states 
such as atherosclerosis and diabetes.  
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Numerous homeostatic biological processes are highly dependent on a class of 
proteins known as nuclear receptors.  These receptors can work together as either 
heterodimers or homodimers to regulate genes pertaining to metabolism.  A general 
nuclear receptor is composed of a N-terminal domain, DNA binding domain, ligand 
binding domain and a C-terminal domain.  The ligand-binding domain is a key aspect 
of nuclear receptors since a ligand could induce a change in secondary structure, 
resulting in transcriptional changes, which would presumably have an effect on 
metabolism.  Genetic regulation is dependent on ligand binding to initiate 
transcription where ligands include steroid hormones, lipids and other molecules for 
metabolic regulation.  Since nuclear receptor ligands bind with high specificity, a 
defect in the ligand-binding pocket can cause detrimental effects to the cell where the 
ligand is unable to bind, thus transcription does not occur for a particular gene.  This 
ligand specificity can be utilized to engineer synthetic ligands, potentially directing a 
cell to activate or inhibit transcription.  Nuclear receptor signaling and dimerization 
are intrinsically linked and critically relevant to therapeutic medicine.  Three nuclear 
receptor proteins of interest are the peroxisome proliferator-activated receptor alpha 
(PPARα), liver X receptor alpha (LXRα) and retinoid X receptor alpha (RXRα), all of 
which contain transactivation and transrepression functions [2].  Nuclear receptors  
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play a key role in biological processes, covering a diverse range of diseases and 
disorders that are a primary focus for study.   
Diseases such as atherosclerosis, hypertension, insulin resistance and 
hypertriglyceridemia stem from metabolic disorders linked to diabetes, often resulting 
from obesity [2].  Nuclear receptors, such as PPARα and LXRα, regulate lipid 
homeostasis and are closely linked to aspects of metabolic function, such as 
inflammation, driven by macrophages in arterial walls [2].  Accordingly, therapeutic 
treatment calls for pharmaceutical profiles, which can exclusively target mis-
regulated homeostatic pathways, driven by these nuclear receptors.   
 
PPAR 
First discovered in the 1990’s (Rakhshanderhoo et. al, 2010), the PPAR 
nuclear receptor has been shown to modulate homeostatic effects pertaining to 
lipoprotein metabolism and other physiological outcomes related to fatty acid 
synthesis and regulation [1].  Certain isoforms exist for each receptor protein, for 
example, there are three subtypes of PPAR including PPARα, PPARδ and PPARγ.  
Each isoform is known to dimerize with the retinoid X receptor (RXR) to carry out 
metabolic processes throughout the body.  Similarities for the subtypes include 
natural ligands since all PPAR’s tend to bind eicosanoids and fatty acids.  However, 
each isoform exhibits differences in metabolic function depending on tissue 
specificity.   
The alpha isoform of PPAR resides in the liver and muscle, responsible for 
regulation of glucose metabolism, ketone body synthesis and fatty acid oxidation [4].  
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Natural ligands such as unsaturated fatty acids bind to PPARα with high affinity 
while saturated fatty acids demonstrate lower affinity binding [4].  Additionally, other 
studies have shown that PPARα binds to 8-(S)-hydroxyeicosatetraenoic acid, another 
endogenous ligand, which is linked to inflammatory responses [4].  Natural ligands 
have characteristically high binding affinities (nanomolar range), therefore a proposed 
explanation includes a promiscuous ligand-binding pocket, possessing the ability to 
bind a host of endogenous lipid derivatives [4].  Synthetic ligands are often used to 
study binding affinities as well, the most commonly studied being fibrate drugs.  
These drugs are currently used in pharmaceutical approaches to lower triglycerides 
and raise high-density lipoprotein (HDL) cholesterol levels, providing a beneficial 
response for patients suffering from hypertriglyceridemia [4].       
The PPAR gamma subtype can be found in adipose tissue, liver and muscle, 
where it is responsible for fat synthesis and storage [4].  By promoting triglyceride 
storage and adipocyte formation, PPARγ is intrinsically involved in insulin 
sensitivity, which is a point of interest for therapeutic drug development [4].  Natural 
ligands for PPARγ include unsaturated fatty acids such as eicosapentaenoic acid, 
arachidonic acid, oleate and linoleate as well as some prostaglandins [4].  Synthetic 
ligands for this isoform include antidiabetic compounds such as thiazolidinediones 
(TZD).  Lastly, the PPAR delta isoform partakes in thermogenesis and fatty acid 
oxidation.  Although PPARδ is ubiquitously expressed, it can fulfill PPARα 
requirements such as fatty acid oxidation in the absence of PPARα [4].   
 Metabolic effects seen by PPAR are dictated by a genetic sequence known as 
the peroxisome proliferator response element (PPRE).  This PPRE is separated by one 
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nucleotide (direct repeat-DR1) and is known to contain a direct repeat consisting of 
the sequence, AGGTCA [1].  Additionally, PPAR is responsible for regulating genes 
such as the fatty acid binding protein 1 (FABP1), peroxisomal acyl-coenzyme A 
oxidase (ACOX1), apolipoprotein A1 (APOA1), ATP-binding cassette transporter 
(ABCA1) and others pertaining to lipid metabolism.   
This nuclear receptor targets the enzyme, HMG-CoA synthase, aiding in 
ketone body production [2].  Particularly, the alpha isoform is of significance since it 
is found in the liver where abnormal regulation results in the chronic diseases 
associated with obesity and diabetes [5].  With regards to therapeutic treatment, 
PPARα has been shown to increase insulin sensitivity in mice, suggesting its 
regulation could be of potential benefit for diabetic human patients [2].   Effects seen 
by PPARα can be manipulated by synthetic ligands, providing metabolic benefits 
where synthetic ligands targeting PPARα, have been shown to decrease triglyceride 
levels and increase HDL’s in plasma, leading to clinical treatment for diseases such as 
hyperlipidemia [1].  Accordingly, PPARα is an attractive target for therapeutic agents 
due to its large, hydrophobic ligand-binding pocket (1300-1400 Å) and ability to bind 
multiple targets, in which a host of synthetic ligands become available [6, 7, 8].   
 
LXR 
 The liver X receptor (LXR) exists in two isoforms, alpha and beta, which play 
a role in cholesterol homeostatic pathways by binding oxysterols.  The beta isoform is 
ubiquitous while the alpha isoform shows tissue specificity, exhibiting feedback 
regulation [2].  Primarily focusing on LXRα, many target genes have been identified, 
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where protein expression is found in the kidney, intestine, liver and adipose tissue, 
where mis-regulation results in diseases linked to obesity and diabetes [9].  Among 
the first genes identified as targets of LXRα regulation was cholesterol 7α-
hydroxylase (CYP7A1), leading to the conclusion that LXR has a regulatory role in 
bile acid synthesis [9].  Additional genes targeted for LXRα regulation include the 
sterol regulatory element-binding protein (SREBP-1), ATP binding cassette genes 
(ABC), lipoprotein lipase (LPL), cholesterol regulatory element binding protein 
(ChREBP), and apolipoprotein (ApoE), all of which maintain cholesterol homeostasis 
throughout the human body.  Liver X receptor alpha target genes also assist in reverse 
cholesterol transport, particularly linked to the liver and intestine.   
 Interestingly, LXRα is known to dimerize with RXRα, binding to two direct 
repeats (AGGTCA) [9].  Each direct repeat is divided by a four-nucleotide segment 
(DR4), known as the LXR response element (LXRE) [9].  Additionally, it has 
recently been shown that LXRα can dimerize with PPARα as well, however, cellular 
effects are not well understood.  Previously identified natural ligands for LXRα are 
24-(S), 25-epoxycholesterol and 22-(R)-hydroxycholesterol, found in the liver and 
adrenal gland, respectively [9].  Other natural ligands include oxysterols, where the 
liver X receptor can serve as a “cholesterol sensor” by up-regulating genes to enhance 
cholesterol transport and catabolism when oxysterol concentrations are elevated [9].  
Therefore, detrimental effects seen with high cholesterol could be regulated by target 
genes activated through LXRα, linking this nuclear receptor to cholesterol 
metabolism.   
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 Regarding diseases, such as atherosclerosis, it has been shown that genetic 
influence can have beneficial effects on metabolic regulation.  For example, a study 
using hypercholesterolemic mice demonstrated a beneficial decrease in 
atherosclerosis when the ABCA1 gene (an LXRα target) was overexpressed [2].  
Furthermore, results from this study indicated a reduction in atherosclerosis 
proliferation, leading to the conclusion that LXR’s possess antiatherogenic properties 
in mice [2].  Therefore, it is possible that synthetic agonists for LXRα could yield 
beneficial effects for humans as well, potentially reducing circulating triglycerides.  
However, LXR drugs in particular have been known to cause detrimental side effects 
in mice and hamsters, such as elevated triglycerides and phospholipids, presumably 
via the SREBP-1 pathway [10].  Interestingly, deletion of LXRα in mice has 
effectively eliminated the negative side effect of increased triglycerides, while the 
beneficial effect of elevated plasma HDL was unaltered [11].  With regards to drug 
development, this data would suggest that pharmaceutical strategies which lower 
hepatic LXR’s or circumvent the liver, would be a viable approach to treating 
cholesterol anomalies such as cardiovascular disease [11].   
 
RXR 
 The retinoid X receptor (RXR) is linked to heterodimer formation with other 
nuclear receptor proteins.  Similar to the other nuclear receptors, RXR has three 
isoforms: alpha, beta and gamma.  Isoform function is not well understood due to the 
vast network of intrinsic pathways linked to retinoic acid.  Studies regarding these 
three isoforms suggest the alpha isoform is ubiquitously expressed, while the beta and 
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gamma isoforms are more restricted [12].  Analysis of in vivo beta transcripts in early 
stages of embryonic development and adult tissues suggests that this isoform plays a 
role in epithelial differentiation [12].  The gamma isoform of this receptor displays 
increased complexity since expression fluctuates throughout regions of the 
mesenchyme during embryonic development [12].  The alpha isoform is the focus of 
this project due to its ubiquitous distribution, suggesting a role in homeostatic 
pathways linked to LXRα and PPARα.   
 With regards to natural ligands, RXRα is known to bind 9-cis retinoic acid 
and can also form homodimers and tetramers in the absence of a DNA template [13].  
Furthermore, RXRα is known to form heterodimers with PPARα and LXRα, both 
with flexible functionality due to tissue specificity.  Interestingly, RXR is sometimes 
referred to as a “silent” partner since dimerization is not dependent on binding 9-cis 
retinoic acid [14].  However, this effect is not exclusive since RXR can be an “active” 
partner as well, such is the case for the PPAR-RXR heterodimer, where both proteins 
exhibit synergistic effects in the presence of ligands [14].   Ligand binding is a point 
of interest as cellular effects are characteristically mediated through allosteric changes 
via the ligand-binding domain [14].   
The retinoid X receptor uses a specific response element (RXRE) consisting 
of a direct repeat (PuG(G/T)TCA) [12].  The spacing between this polymorphic motif 
is variable, ranging from a DR1 to DR5.  Heterodimers can form in the presence or 
absence of DNA where target genes for the RXRα-LXRα and RXRα-PPARα 
heterodimers include cholesterol 7α-hydroxylase (CYP7A1) and apolipoprotein A1 
(APOA1), respectively [15].  Target genes specifically for RXRα remain elusive due 
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to the ubiquitous role of RXRα in metabolic pathways, therefore, regulation of gene 
expression is a point of interest for synthetic ligand development.  
 
Heterodimers 
Each receptor protein can dimerize in three different fashions: PPARα-RXRα, 
LXRα-RXRα and PPARα-LXRα, where natural ligands can influence cholesterol and 
lipoprotein metabolism. [3].  The present day goal is to manipulate each heterodimer 
with a synthetic ligand, providing benefits for patients with clinical diseases.  In order 
to determine an effective synthetic ligand for the heterodimer of interest, knowledge 
of metabolic effects for each heterodimer is imperative.   
The PPARα-RXRα heterodimer is known to target genes pertaining to fatty 
acid oxidation.  This heterodimer is a key component in mitochondrial and 
peroxisomal β-oxidation where natural ligands include fatty acids and fatty acyl-
CoAs, further aiding in pathways regarding high-density lipoproteins (HDL) and low-
density lipoproteins (LDL).  With respect to synthetic ligands, drugs such as statins 
function as HMG-CoA reductase inhibitors.  By inhibiting HMG-CoA reductase, 
cholesterol levels are significantly reduced, presumably providing beneficial effects 
for patients with hypercholesterolemia and hyperlipidemia.  Other antiatherogenic 
compounds have been studied, however, none have been FDA approved due to 
negative side effects.  Current medical treatment for metabolic diseases such as 
diabetes and atherosclerosis include synthetic ligands such as fibrates, known targets 
of the PPARα-RXRα heterodimer, which induce peroxisomal proliferation.  Clinical 
effects of fibrates include a reduction in triglyceride levels and an increase in HDL 
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levels [1].  Knowledge of these heterodimeric proteins becomes critically important 
when treating diseases related to cholesterol and lipid metabolism. 
Correspondingly, the LXRα-RXRα heterodimer is known to regulate genes 
pertaining to cholesterol metabolism.  This heterodimer is tissue specific, meaning 
biological effects can differ depending on tissue type.  For example, in the intestine, 
LXRα-RXRα may assist in cholesterol reabsorption and excretion whereas in the 
liver, it may aid in bile acid synthesis [6].  Overall, cholesterol levels throughout the 
body can be regulated via the LXRα-RXRα heterodimer.  These natural processes are 
affected by endogenous ligands including oxysterols and hydroxycholesterols, where 
ligand binding initiates transcription.  With regards to medicinal research, synthetic 
counterparts include antiatherogenic compounds such as ticlopidine, nicotinic acid 
etofibrate, which are designed to achieve metabolic effects similar to natural 
processes.  Currently, there are no drugs on the market known to target this particular 
heterodimer due to highly adverse side effects.   
It has been shown that nuclear receptor proteins PPARα and LXRα dimerize 
as well [3], for which cellular effects are not fully understood.  Recent data suggests 
this heterodimer regulates genes targeting cholesterol lipoprotein metabolism.  
Furthermore, it has been shown that LXRα ligands improve effects caused by the 
PPARα-LXRα heterodimer, directly impacting the formation of other heterodimers as 
well [3].  Accordingly, it has been discovered that the formation of PPARα-RXRα 
and LXRα-RXRα are greatly reduced with the addition of PPARα and LXRα 
agonists, respectively [3].  This knowledge becomes acutely important when treating 
patients with synthetic ligands targeting cholesterol or fatty acid pathways pertaining 
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to diabetes.  Since effects of the PPARα-LXRα heterodimer are relatively unknown, it 
is possible that current drugs directly affect this heterodimer and have effects on 
unanticipated cellular processes that are potentially detrimental to the cell.  Therefore, 
knowledge of synthetic ligands and their corresponding in vivo effects is a key 
interest for novel drug discovery.  
 
Cross Talk 
 Nuclear receptor proteins, PPARα, LXRα and RXRα, are intrinsically linked 
where one protein can affect the dimerization and transcriptional activities of another 
heterodimer pair.  Previous discoveries indicate PPARα can negatively affect the 
formation of the LXR-RXR heterodimer, down-regulating the SREBP-1c genetic 
pathway targeted by LXR [16].  The human body displays an abundance of 
coordinated metabolic networks, specifically regarding fatty acid synthesis and 
storage.  Utilization and storage of fatty acids is a reciprocally coordinated process, 
regulated by cross-talk between nuclear receptors, further complicating synthetic 
ligand discovery [16].  Interestingly, the addition of a LXR ligand causes an increase 
in LXRα-PPARα heterodimer formation, while the addition of both PPARα and LXR 
agonists result in simultaneous reduction of heterodimer formation regarding PPARα-
RXRα and LXRα-RXRα [3].  Cross-talk between these receptors allows for a 
coordinated control of regulatory genes providing metabolic homeostasis throughout 
the body.  This cross-talk also adds another level of complexity to human cholesterol 
and fatty acid metabolism, complicating pharmaceutical development for diseases 
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such as atherosclerosis and diabetes.  Accordingly, therapeutic treatment requires 
extensive scrutiny since drug targets may not be exclusive.   
 
Ligand-Binding Domain  
 Ligand binding is crucial for initiation of cellular effects via transcription.  
Binding sites are often specific to a certain ligand in terms of secondary structure or 
spatial geometry, and are a point of interest for drug development.  With regards to 
ligand binding, nuclear receptor proteins contain ligand-binding sites consisting of 
alpha helices [2].   Nuclear receptors also contain DNA binding sites composed of 
zinc finger motifs [2].  Interestingly, the presence of DNA is not required for 
dimerization, however, DNA binding is enhanced when both domains are present.  
Ligand binding for these proteins is driven by the C-terminal ligand-binding domain 
(LBD), acting as a guide for the recruitment of co-activator complexes, leading to 
gene regulatory functions such as histone methyltransferase and nucleosome 
remodeling [2].  Correspondingly, without the presence of a ligand, nuclear receptor 
heterodimers are known to inhibit transcription via co-repressors [2].  The 
significance of ligand-binding transcriptional effects is an attractive topic for further 
study, especially with regards to synthetic ligands, leading to potential cures for 
metabolic diseases linked to obesity and diabetes.   
 Synthetic ligands are often designed as an agonist or antagonist, targeted for 
either activation (agonist) or inhibition (antagonist) of certain genes.  If an agonist or 
antagonist can be made to look similar to a natural ligand, it is possible that the ligand 
can bind to a nuclear receptor and affect transcription.  As these ligands bind, the 
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nuclear receptor proteins undergo a conformational change, altering protein function 
via transcriptional affects.  In the case of an antagonist, conformational changes may 
occur where the natural ligand can no longer fit into the binding pocket.  This could 
benefit diseases, such as atherosclerosis, where negative metabolic effects may be 
inhibited.  Alternatively, an agonist could work to activate pathways, which may not 
normally be active, leading to beneficial effects for diseased patients.  Pharmaceutical 
development is influenced by knowledge of ligand binding, leading to discoveries 
pertaining to cholesterol and lipoprotein metabolism.   
 
Natural and Synthetic Ligands 
The ligand-binding domain (LBD) of nuclear receptors, PPARα, LXRα and 
RXRα, can mediate cellular processes via transactivation and transrepression 
functions [2].  Interestingly, the ligand-binding domain encodes several functions 
including dimerization, ligand binding, transactivation and binding to co-repressors 
and co-activaors, thus the LBD plays a significant role in metabolism [17].  
Regarding human metabolism, natural ligands such as cholesterol metabolites and 
fatty acids bind PPARα and LXRα with lower affinities (micromolar range) than their 
steroid counterparts (nanomolar range) [2].  
Previous in vitro studies have utilized surface plasmon resonance (SPR) to 
study the effects of ligands on heterodimer pairs, specifically regarding the ligand-
binding domain [17].  This particular study is one of the only studies that have 
evaluated the effects of ligands on heterodimer pairs, as opposed to the individual 
nuclear receptor proteins themselves [17].  Their published data utilized a fibrate 
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drug, Bezafibrate, which was shown to have an incremental effect on the LBD of both 
PPARα and LXRs [17].  With regards to chemical interactions, it was found that 
hydrogen bonding was affected while hydrophobic interactions showed no change 
upon ligand binding [17].  This study was one of the first to show that ligand binding 
can have an effect upon dimerization, leading to altered genetic expression in a 
variety of tissues [17].   
 The three nuclear receptors, LXRα, PPARα and RXRα, possess several 
similarities in regards to ligand binding.  It is known that the PPARα-RXRα complex 
binds to polyunsaturated fatty acids, while the PPARα-LXRα complex binds to fatty 
acyl-CoA’s.  Consequently, it is possible that a ligand for one nuclear receptor protein 
could also serve as a ligand for a partner nuclear receptor protein.  This could have a 
significant effect on genetic transcription in response to dimerization.  Cross-ligand 
binding suggests that binding may not be exclusive, therefore, it is clinically 
significant to test specificity of ligand affinity.   
Previous lab data identified that ligand binding does affect dimerization, 
suggesting that ligand binding determines heterodimer choice.  It is important to 
recognize which sets of genes are being affected by certain ligands in order to 
accurately treat diseases.  For example, it is well known that fibrates have an effect on 
lipoprotein levels by increasing HDL’s and decreasing triglycerides, providing 
beneficial outcomes for patients with hypertryglyceridemia [2].  Since fibrates are 
known PPARα agonists, it is largely assumed that the PPARα-RXRα heterodimer is 
the main target since genes involving fatty acid oxidation are affected.  Yet, it is 
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possible there could be unexpected effects on genetic targets regulated by the LXRα-
PPARα heterodimer, potentially affecting genes that are not well understood.      
 The goal of this thesis project is to test multiple synthetic ligands with each of 
the three heterodimers to evaluate protein-protein binding affinities and other cellular 
interactions.  Knowledge of how these ligands interact with heterodimers formed 
from PPARα, LXRα, and RXRα could provide valuable insight for therapeutic 
medicine.  Ligands to be tested include: Auraptene, Ciprofibrate, Fluorobexarotene, 
GW-6471, Lovastatin, Pravastatin Sodium Salt, UVI 3003 and  
T-0901317 (Figure 1).  
  















Figure 1.  Synthetic compounds and their corresponding structures. 
 
 Due to the regulatory role of PPARα in cholesterol and free fatty acid 
homeostasis, fibrate drugs have shown the most promise for therapeutic benefit.  
Currently on the pharmaceutical market, fibrates and statins allow synthetic 
regulation of free fatty acids and triglycerides, relevant to diabetes and 
atherosclerosis.  Ciprofibrate is one member of the fibrate family, which is a known 
PPARα agonist.  Previous research has indicated that fibrates can regulate free fatty 
acids, triacylglyceride homeostasis and lipoprotein levels, making fibrates highly 
beneficial to hypertriglyceridemic individuals [2].  Fibrates are also known to protect 
against atherosclerosis by stimulating high-density lipoproteins (HDL) and regulating 
lipid homeostasis [7].  Fibrates particularly act through the ABCA1 gene, which is 
responsible for maintaining lipid and cholesterol homeostasis [18].  Accordingly, the 
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ability of fibrates to target this gene allows for increased transcription, resulting in 
elevated HDL levels, benefiting patients suffering from atherosclerosis and coronary 
heart disease [18].  However, fibrate drugs can also cause negative side effects, the 
most common being gastrointestinal problems [19].  In addition to dyspepsia, fibrates 
can make patients prone to gallstones due to elevated biliary cholesterol [19].  
Furthermore, statins can also have beneficial outcomes for individuals with high 
cholesterol, inhibiting cholesterol synthesis and promoting the conversion of 
cholesterol to bile acids.  This research will primarily focus on lovastatin and 
pravastatin sodium salt.  Interestingly, previous studies have shown that lovastatin 
can induce transcription of the gene CYP7A1, which codes for an enzyme that 
participates in the rate-limiting step of bile acid synthesis.  Stimulation of this gene 
allows for elevated bile acid synthesis in the liver, leading to a possible interaction 
with LXRα [20].  Furthermore, lovastatin and pravastatin sodium salt function as 
HMG-CoA reductase inhibitors, helping lower cholesterol levels throughout the 
body.  Although these drugs have therapeutic relevance and seemingly beneficial 
outcomes, the undesired side effects cannot be ignored.  It has been shown that statins 
can induce myopathy, where detrimental effects are worsened when combined with a 
fibrate [19].  By further understanding the interaction of nuclear receptor proteins 
with these drugs, side effects could potentially be eliminated, making fibrates and 
statins invaluable to diabetic patients, as well as patients with fatty acid and 
cholesterol disorders.  Furthermore, these are intriguing drugs to study due to the 
wide effects on energy metabolism, specifically concerning cross-talk and regulation 
of the heterodimers formed by PPARα, LXRα and RXRα.   
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Correspondingly, the only antagonist known for PPARα is GW-6471 (Xu et. 
al), for which very little is known.  This drug was originally designed to test the 
binding of corepressors with PPARα [21].  Modified from the PPARα agonist GW-
409544, the GW-6471 ligand contains an amide group instead of a carboxylate group, 
making this a functional PPARα antagonist [21].  This antagonist functions by 
disrupting coactivator complexes of nuclear repressors, thus promoting the 
recruitment of corepressors such as Silencing Mediator for Retinoid and Thyroid 
hormone receptors (SMRT) and Nuclear CoRepressor (N-CoR) [21].  The hope is 
synthetic compounds like this could provide symptomatic relief for hypertriglycemic 
and diabetic individuals with minimal side effects.   
 Commonly studied RXR agonists include bexarotene, also known as  
4-[1-(3,5,5,8,-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic Acid), 
generically known as Targretin.  This drug is currently used to treat patients with 
cutaneous T-cell lymphoma since it can inhibit metastasis and initiate apoptosis [22].  
Current side effects include increased lipid levels and high cholesterol, making this an 
attractive target for clinical research [22].  Genes involved in lipid homeostasis can be 
targeted by this compound, including sterol regulatory element-binding transcription 
factor 1 (SREBP-1c), Stearoyl-CoA desaturase-1 (SCD1), fatty acid synthase 
(FASN), as well as ATP-binding cassette, sub-family G (ABCG5 and ABCG8) [23].  
In fact, the tissue specificity of the LXR-RXR heterodimer was discovered through a 
study using bexarotene, to observe effects on target genes such as ABCG5 and 
ABCG8 [23].  By analysis of mRNA levels, it was discovered that expression of these 
genes differed in the liver and intestine, suggesting tissue specificity of the LXR-
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RXR heterodimer [23].  A previous study designed and tested multiple analogues of 
bexarotene where it was determined that non-hydrogen functional groups, substituted 
on the aromatic ring close to the carboxylic acid, exhibited increased binding affinity 
for RXRα [24].  The derivative fluorobexarotene was chosen for study due to a 75% 
increase in binding affinity when compared to bexarotene alone, which was the 
greatest of all analogues tested [24].  It was determined that this novel RXRα ligand 
also demonstrates minimal activity as an RAR agonist, thus negative side effects may 
be lessened in therapeutic use.  Target genes affected by fluorobexarotene are 
unknown, however, it is likely that genetic regulation is similar to that of bexarotene 
since the molecular structures are similar.     
Correspondingly, an RXR antagonist was chosen for study as well.  The 
particular RXR antagonist chosen, UVI-3003, has been previously used to study the 
specific role of RXR in the differentiation of adult alveolar epithelial cells, for which 
research is still in its infancy [25].  The goal of this previous study was to determine if 
RXR was acutely responsible for epithelial cell differentiation in human lungs by 
inhibiting RXR effects using UVI-3003 [25].  It was determined that RXR is 
responsible for cellular differentiation, however, unequivocal results can be difficult 
to obtain since RXR plays a role in biological processes such as the transforming 
growth factor beta (TGFB) and hepatocyte nuclear factor 4 alpha (HNF4A) pathways 
[25].  Even though little is known about the specific function of RXR, it has been 
shown that cells can be rescued from antagonizing effects seen with UVI-3003, 
suggesting that potential negative side effects of this medication could be reversed 
[25].  Yet, the precise point of regulation is highly dependent upon protein-protein 
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interactions within the cell, therefore, it is necessary to study the effects of these 
drugs on heterodimers formed by PPARα, LXRα and RXRα to better understand 
regulatory effects, relevant to therapeutic medicine.   
 Regarding LXRα, a well-studied synthetic ligand of interest is the T-0901317 
compound [26].  Previously discovered target genes include: ABCA1, acetyl-CoA 
carboxylase, SCD1, SREBP-1c and FAS [26].  The T-0901317 ligand functions as an 
agonist for LXRα, providing treatment for clinical patients suffering from low levels 
of HDL’s [26].  Although this ligand has therapeutic relevance and seemingly 
beneficial outcomes such as elevated HDL levels, the undesired side effects cannot be 
ignored.  None of the drugs targeting LXRα have been FDA approved due to negative 
side effects.  For example, the T-0901317 compound can induce lipogenesis leading 
to an increase in HDL’s, resulting in elevated liver and plasma triacylglycerols [26].  
Studies have shown that these negative effects in plasma are transient, however, 
detrimental effects of triacylglycerol levels in the liver are less understood [26].  
Furthermore, this LXRα agonist has been shown to decrease atherosclerosis in mice 
by lowering hepatic cholesterol [11].  While some studies hold promise for success, it 
is still important to understand which cellular processes are being targeted in regards 
to transcriptional regulation via heterodimers formed by RXRα, LXRα and PPARα.  
This is especially necessary in therapeutic medicine to achieve a high success rate, 
with minimal adverse side effects.   
 Ligands of clinical significance are not exclusively synthetic; one unique 
biochemical compound of interest has been proposed to target LXRα, exhibiting 
antagonizing effects [27].  This compound, auraptene, is classified as a citrus 
	   20 
phytochemical and exists as a monoterpene coumarin ether [27].  Auraptene, isolated 
from Citrus ichangensis peel extract, has been shown to arrest triglyceride and lipid 
proliferation in adipocytes, thus providing benefits for patients suffering from 
metabolic disorders related to obesity [27].  Interestingly, auraptene appears to have 
more than one nuclear receptor target.  Derivatives of this compound can affect LXR 
target genes by inhibiting expression of genes such as apolipoprotein E (ApoE), 
cytochrome P450 7A1 (CYP7A1), and lipoprotein lipase (LPL), suggesting auraptene 
functions as an LXR antagonist [27].  With regards to PPAR, the ability of auraptene 
to restore insulin sensitivity and regulate glucose homeostasis demonstrates complex 
regulation of PPARα and PPARγ, suggesting auraptene could act as a general PPAR 
agonist [27].  Furthermore, auraptene derivatives were shown to decrease expression 
of PPARγ target genes such as fatty acid synthase (FAS), acyl-CoA oxidase (ACOX) 
and uncoupling protein 2 (UCP2) [27].  Since auraptene derivatives exhibit cross-talk 
between PPAR and LXR, it is possible that auraptene binding is not exclusive and 
multiple receptors could be affected.  This promiscuous binding could result in 
unforeseen negative side effects, leading to complications in therapeutic treatment of 
diseases related to obesity and diabetes.   
 Ligand-binding is a point of interest and can affect multiple aspects of 
heterodimer formation such as stereochemistry, binding affinity and protein-protein 
interactions.  Accordingly, evaluation of the novel heterodimer PPARα-LXRα can 
provide valuable insight into therapeutic treatment regarding obesity and diabetes, 
allowing for a deeper understanding of pharmaceutical repercussions and side effects.    
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II. HYPOTHESIS AND AIMS 
 
 
Experimental techniques will be utilized to evaluate the hypothesis that 
ligand binding determines the relative binding affinities and subcellular 
localization of nuclear receptors.  Procedures and techniques used to test this 
hypothesis will focus on the heterodimer pair formed by PPARα and it’s partner 
receptor LXRα. 
 
Aim 1:  The goal is to determine if synthetic ligands modulate the formation of 
heterodimer pairs. 
 
Protein-ligand interactions will be evaluated using intrinsic fluorescence 
quenching to establish ligand exclusivity.  Additionally, fluorescence resonance 
energy transfer (FRET) will be primarily used to evaluate effects of synthetic ligands 
on protein-protein interactions.  These assays will help narrow the scope of drugs to 
be tested in aim 2.  Ligands that induce significant changes in the binding affinities of 
heterodimeric partners will be utilized for further testing.  Circular dichroism will be 
implemented to test for differences in secondary structures caused by ligand binding 
and protein dimerization. 
 
Aim 2:  The goal is to determine the effects of ligands on subcellular localization of 
PPARα, LXRα and RXRα.   
 
 Bimolecular fluorescence complementation (BiFC) will be used to visualize 
the effects of ligands on subcellular localization in vivo using COS-7 cells.  Cells 
transfected with BiFC fusions of PPARα and LXRα will be used to evaluate the 
hypothesis.  Fluorescence microscopy provides an in vivo assay where subcellular 
localization of heterodimer pairs can be visualized based on quantitation of 
fluorescence. 	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III. MATERIALS AND METHODS 
 
Plasmid Construction for hPPARα, hLXRα and hRXRα 
All experiments employed the use of full-length human PPARα, LXRα and 
RXRα.  Expression plasmids were pre-existing in the lab, and were constructed using 
the methods described below.  Plasmids for producing purified proteins were 
constructed by adding an N-terminal polyhistidine tag (six His residues) to the 
Glutathione S transferase (GST) open reading frame in the pGEX6P vector 
(Amersham Biosciences, Piscataway, NJ) via overlap polymerase chain reaction 
(PCR).  The result consists of six histidine residues and a GST tag upstream of a 
PreScission Protease site and a multiple cloning site, amplified from complimentary 
DNA [28, 29].  Each nuclear receptor was derived from HepG2 cells using 












Figure 2.  Primers used for amplification from cDNA derived from HepG2 cells.  (A) 
Primers used for hPPARα. (B) Primers used for hLXRα. (C) Primers used for hRXRα.  
Nucleotides outside of the target sequence are represented by lower case letters with the 
restriction site underlined.   
 
 
A  5’-cggatccATGGTGGACACGGAAAGCCC-3’  
5’-cgtcgacCTATCAGTACATGTCCCTGTAG-3′ 
 
B  5’- ggatccATGTCCTTGTGGCTGGGGGCCCCTGTG-3’ 
5’-aagcttCTCGAGTCATTCGTGCACATCCCAGATCTC-3’ 
 
C  5’-cgaattcATGGACACCAAACATTTCCTGCCGCT-3’ 
5’-ctcgagCTAAGTCATTGGGTGCGGCGCCTCC-3’ 
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Following PCR, the products were cloned into the pGEM-T easy vector 
(Promega Corporation, Madison, WI) for sequencing and subsequently transferred 
into the Bam HI/SalI, BamHI-HindIII or EcoRI-XhoI sites of the pGEX-6P derivative 
to produce 6xHis-GST-hPPARα (Figure 3A), 6xHis-GST-hLXRα (Figure 3B) and 
6xHis-GST-hRXRα (Figure 3C), respectively [28, 29].  These ampicillin-resistant 
plasmids were further transformed into Rosetta 2 competent cells for protein 
expression. 
	  
	   	  






































Figure 3.  Schematic of plasmid DNA constructs for full-length His-tagged proteins.  (A)  
Representation of the cDNA encoding hLXRα, constructed by adding an N-terminal 
polyhistidine tag (six His residues) to the Glutathione S transferase (GST) open reading frame 
in the pGEX6P vector.  (B) Representation of the cDNA encoding hPPARα, constructed by 
adding an N-terminal polyhistidine tag (six His residues) to the Glutathione S transferase 
(GST) open reading frame in the pGEX6P vector.  (C) Representation of the cDNA encoding 
hRXRα, constructed by adding an N-terminal polyhistidine tag (six His residues) to the 
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Recombinant Protein Purification 
	  
i. Protein Expression in Escherichia coli  
Plasmids for recombinant protein expression were transformed into Rosetta 2 
competent cells (Novagen), plated onto selective media and incubated at 37°C 
overnight.  For each protein, an overnight bacterial culture of 200 ml was grown from 
5 colonies at 30°C and shaken at 200 rpm in Luria Bertani (LB) media (Sigma 
Aldrich) containing 10% glucose, 2 mg chloramphenicol and 10 mg ampicillin.  The 
following morning, the 200 ml culture was sub-cultured into two 1L flasks containing 
LB (100 ml culture per 1L) and propagated at 37°C for approximately 3 hours or until 
the optical density (OD600) reached 1.1-1.3.  After achieving the proper OD, 1 ml of 
0.1M isopropyl β-D-1-thiogalactopyranoside (IPTG) was used in each liter to induce 
protein expression where the resulting mixture was allowed to incubate at 16°C for 4 
hours.  Subsequently, bacterial cells were pelleted by centrifugation, using an Avanti-
J26 XPI centrifuge JA-10 rotor, at 4°C with a speed of 8500 rpm for 10 minutes.  
Following centrifugation, 100mM of protease inhibitor, phenylmethylsulfonyl 
fluoride (PMSF), was added to each pellet and stored at -80°C overnight.     
	  
ii. Purification via Affinity Chromatography 
Protein purification was conducted by applying a soluble protein fraction to a 
glutathione cartridge (Bio-Rad Inc.); followed by washes and on-column cleavage of 
the GST tag.  A soluble protein fraction was created by re-suspending the pellet from 
a 1L culture in 10 ml of 2X L&C buffer (25000mM Tris, pH 8.0, 20% glycerol and 
590mM NaCl), 500mM EDTA, 100mM DTT and 10 ml 2X protease inhibitor 
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(SIGMAFASTTM protease inhibitor cocktail tablet, EDTA-free, Sigma-Aldrich).  The 
bacterial cells in the resulting mixture were lysed via sonication at 6 intervals of 30 
seconds on/off at 50% amplitude using a Fisher Scientific© sonic dismembrator, 
model 150E.  The mixture was then centrifuged using an Avanti-J26 XPI centrifuge 
with a JA-25.50 rotor at 10,000 rpm for 30 minutes.  The cell lysate was collected and 
filtered using a 1.2 micron filter, loaded onto the glutathione column and purified by 
affinity chromatography.  A flow rate of 0.1 ml per minute was used for loading the 
column and for subsequent washes.  First, the column was allowed to equilibrate with 
5 ml of 1X L&C buffer (25000mM Tris, pH 8.0, 20% glycerol and 590mM NaCl).  
Secondly, an ATP buffer (5 ml consisting of 2X L&C buffer, 10mM ATP and 50mM 
MgCl2) was applied, followed by a third buffer consisting of 10 ml 1X L&C 
(containing 0.5mM EDTA and 1mM DTT), thus removing any unbound protein from 
the column.  In order to elute the bound protein of interest from the GST column, a 
mixture of PreScission protease (1 ml 1X L&C, 0.5mM EDTA, 120 ug protease, 
1mM DTT) was applied.  Elutes were collected in 1 ml fractions containing 10% 
glycerol and 200 µl of 5M NaCl to promote protein stability.  To ensure complete 
removal of pure protein from the GST column, multiple 1 ml elutes were collected.   
	  
iii. Protein Concentration and Purity 
After collecting elutes, protein concentrations were determined via a Bradford 
assay (Bio-Rad Inc.) where 5 µl of sample was mixed with 195 µl of Bradford reagent 
(Bio-Rad Inc.).  Resulting values were compared against bovine serum albumin 
(BSA) standards (Sigma Aldrich) ranging from 0.1 mg/ml to 0.8 mg/ml, where a 
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spectrophotometer was used to record absorbance measurements at 595 nm.  
Accordingly, tabulation of results allowed for extrapolation of absorbance values 
which were compared against a set of standards to yield a linear equation of the form 
y = mx + b.  Using this equation, protein concentrations of eluted fractions were 
established.  These protein fractions were further concentrated by centrifugation using 
a 30KDa or 10KDa filter.  The degree of concentration was dependent on 
experimental parameters for optimal effectiveness.   
Protein purity was established by sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) with Coomassie blue staining.  Protein samples from 
each stage of the purification process were treated with 2X sample buffer containing 
100mM DTT and heated at 90°C for 3 minutes.  Samples were promptly loaded onto 
a 10-12% polyacrylamide gel along with a pre-stained benchmark protein ladder 
(Invitrogen).  The gel was run at a constant amperage of 30V for 60 minutes in 1X 
electrode buffer containing 10% SDS and then imaged using a Fujifilm LAS-4000 
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Protein-Protein Interactions in vitro 
i. Ligand-Binding Assays 
 The first step in this process is to study ligand-binding behavior with a single 
protein by measuring binding affinities using a photon counting spectrofluorimeter 
(PC1).  It is essential to test binding affinities for each ligand with each nuclear 
receptor alone to determine if binding really is exclusive.  For example, it is possible 
that a PPARα agonist, such as ciprofibrate, could potentially bind to LXRα, 
drastically affecting gene targets. Upon further evaluation of heterodimer pairs and 
protein-protein interactions, knowledge of ligand exclusivity becomes critically 
important.  This phenomenon may provide an explanation for negative side effects of 
pharmaceutical compounds, leading to a better understanding of therapeutic treatment 
for diseases linked to obesity and diabetes.   
A photon counting spectrofluorimeter (PC1) was used to measure protein-
ligand interactions in vitro, establishing binding affinities for each ligand tested.  The 
PC1 can measure intrinsic protein fluorescence by exciting tyrosine and tryptophan 
residues at 280nm, where resulting peak emission values can be used to plot the 
change in fluorescence upon titration with a ligand.  A saturable curve is indicative of 
binding, and can be used to estimate the dissociation constant (Kd).  Alternatively, a 
straight line suggests either non-specific binding or lack of binding for a particular 
ligand.  Furthermore, a double reciprocal plot can be utilized to determine the number 
of binding sites on a particular protein.  A linear double-reciprocal plot demonstrates 
a single binding site, whereas a sigmoidal curve suggests two or more binding sites.  
This information is beneficial in determining the affinity of a particular ligand for a 
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certain protein, providing valuable insight to further understand effects of molecular 
homeostatic pathways.  Samples were excited at 280nm with a bandwidth of 0.8mm.  
Emission wavelength was scanned over a range of 310-370nm also using a bandwidth 
of 0.8mm.  All scans were completed without a polarizer using 1mm slits at a 
constant temperature of 24°C.  The protein of interest was titrated with increasing 
amounts of ligand, while readings were taken in intervals of 3 minutes.  For each 
binding experiment, the concentration of protein was verified using a Bradford 
protein assay (Bio-Rad Inc.) to ensure accurate measurements.  Each experiment 
utilized protein fractions at a concentration of 100nM, while sequential ligands were 
prepared at a concentration of 100µM in DMSO and titrated up to 300nM in 
increasing increments.  Molar increments were optimized such that more readings 
were taken in the lower nanomolar range (0-50nM) where binding was most likely to 
occur. 
	  
ii. Circular Dichroism (CD) 
Circular dichorism is a technique that allows for characteristic, structural 
analysis of a given protein.  The far UV region (240-180nm) provides information on 
secondary structure (α helices, β sheets, turns and unordered structures), since the 
peptide bond is the principal absorbing group [30].  Alternatively, the near UV region 
(320-260nm) presents data regarding tertiary structure due to absorption of aromatic 
amino acid side chains [30].  With regards to clinical application, this technique has 
enabled discoveries in degenerative diseases such as bovine spongiform 
encephalopathy (BSE), scrapie and Alzheimer’s disease since the formation of β-
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sheets serves as a precursor to the formation of amyloid fibrils, which are 
characteristic markers of these diseases [30].  Furthermore, this technique can be used 
to identify changes in protein structure upon the addition of certain drugs or ligands. 
Circular dichroism was used to study structural changes in the hLXRα-
hPPARα heterodimer in response to synthetic ligands using a J-815 
spectropolarimeter (JASCO Inc.).  Previously, secondary structures of individual 
proteins were analyzed with endogenous ligands, using the human glucocorticoid 
receptor (hGR) as a negative control [29].  While previous studies focused on 
analyzing individual nuclear receptors, this experiment focused on synthetic ligand 
effects regarding the novel heterodimer, hLXRα-hPPARα.  Synthetic ligands used in 
this study were: fluorobexarotene, ciprofibrate, T-0901317, auraptene and GW-6471.  
All compounds were dissolved in 50% DMSO, except for T-0901317 which was 
dissolved in ethanol.  Each compound was prepared at a concentration of 100µM. 
Ionic strength must be considered when using circular dichroism because the 
ionic strength of a solution in a reaction cuvette can create voltage spikes if the salt 
concentration is too high.  Proteins were concentrated to minimize the volume of 
sample added to the reaction cuvette, therefore decreasing the total ionic strength of 
the system.  Buffer solutions are an important consideration for circular dichroism 
since many salt molecules, such as chloride ions, affect pH and absorb strongly below 
195 nm [30].  Therefore, to minimize absorbance by excessive salt, proteins were 
concentrated to 0.40 mg/ml (hLXRα) and 0.53 mg/ml (hPPARα) in PBS buffer.  For 
all samples, the amino acid concentration was kept at 0.0003M to achieve an 
absorbance intensity of 0.8 within the range of λ = 180-260 nm.  Circular dichroic 
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spectra were obtained for individual proteins hPPARα (0.60µM) and hLXRα 
(0.60µM), alone and in the presence of synthetic ligand (5µM).  More importantly, 
effects of synthetic ligands on secondary structure of the novel heterodimer, hLXRα-
hPPARα, were analyzed by using 0.3µM hPPARα and 0.3µM hLXRα, alone and in 
the presence of ligand (5µM).  Data for each replicate was collected using a 
continuous scan over the far-UV range (180-260 nm) with a bandwidth of 1.0 mm at 
a scan rate of 50 nm/min.  Five scans were averaged for each sample and secondary 
structure composition was compared against a CD Pro, software database using the 
programs CONTIN and SDP42.  Estimates for α-helices, β-sheets, turns and 
unordered structures were established and statistically analyzed using a two-way t-test 
in Sigma Plot©.  Furthermore, molar ellipticity was plotted as a function of 
wavelength to yield characteristic spectra for each sample set.  Heterodimeric 
structure was compared both with and without the presence of ligand to determine 
unique effects of synthetic ligands on the hLXRα-hPPARα heterodimer.   
Each protein alone yields a characteristic CD spectra from which 
computational analysis can be established from an average of five scans.  If two 
proteins interact, the spectra and the estimated composition would presumably be 
altered.  Such is the case with LXRα and PPARα during the formation of a 
heterodimer.  Additional changes in secondary structure could be induced by a 
synthetic ligand, resulting in an altered CD spectrum.  If a synthetic ligand were 
shown to alter the binding affinity of LXRα and PPARα, a change in the CD spectra 
and estimated composition of α-helices, β-sheets, turns and unordered structures 
would be expected.   
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iii. Fluorescence Resonance Energy Transfer (FRET) 
To investigate effects of synthetic ligands on protein-protein interactions 
between LXRα and PPARα, fluorescence resonance energy transfer (FRET) studies 
were completed.  Fluorescence resonance energy transfer consists of two 
fluorescently labeled proteins, which exclusively produce a fluorescent signal upon 
dimerization when excited at the appropriate wavelength.  Each protein bears a 
fluorescent label and the two labels represent a “FRET pair.”  As these proteins 
dimerize, there is an energy transfer from the donor molecule to the acceptor 
molecule, for which fluorescence changes can be visualized.  In order for energy 
transfer to be seen as a change in fluorescence, it is important that the spectra for the 
donor and acceptor molecules overlap slightly, such that a decrease in donor emission 
can be seen, along with an increase in acceptor emission [31].  As an alternative to 
intrinsic quenching assays, FRET studies utilize extrinsic fluorophores to view 
changes in fluorescence, and are suitable for a variety of applications such as 
intermembrane interactions and the study of viral protein envelopes [31].   
 In order to complete FRET studies regarding nuclear receptor proteins, LXRα, 
PPARα and RXRα, each protein must be fluorescently labeled with an extrinsic dye.  
Characteristically in the past, cyanine dyes such as Cy3 and Cy5 have been used to 
study fluorescence quenching via FRET assays [29].  This particular labeling 
technique caused complications due to environmental instability of the fluorophores, 
where conformational changes upon protein dimerization, produced fluorescent 
changes that were greater than effects seen by fluorescence quenching.  Therefore, 
Alexa Fluor dyes were selected for labeling due to greater environmental stability, 
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high quantum yield and low solvent sensitivity.  Chemically, the Alexa Fluor dyes 
were covalently attached to nuclear receptor proteins on primary amines.  Proteins 
were labeled using Alexa Fluor microscale labeling kits (Invitrogen) in combination 
with 3ml slide-a-lyzer G2 dialysis cassettes (Fisher Scientific).  Prior to labeling, 
proteins were dialyzed in PBS (pH 7.5) such that the final buffer did not contain any 
primary amines (ammonium ions, Tris, glycine, ethanolamine, triethylamine or 
glutathione).  Protein concentration prior to labeling was near 1 mg/ml to ensure 
adequate labeling.  To establish proper pH for the labeling reaction, 1/10 volume of a 
1M sodium bicarbonate solution was added to the unlabeled protein.  Subsequently, 
the appropriate amount of dye was added to the protein mixture and allowed to 
incubate at room temperature for 15 minutes.  The resulting solution was transferred 
to a dialysis cassette and allowed to dialyze in 1L of high salt PBS buffer (Table 1).  
The buffer was changed four times before the protein was removed and aliquotted for 
FRET experiments.  After labeling, the concentration and degree of labeling were 
determined for each Alexa Fluor dye reaction.  Ideally, a dye to protein ratio would 
be 1:1 for each reaction, meaning one dye molecule would be attached to one protein 
molecule.  Therefore, the degree of labeling value would be close to 1.  The degree of 
labeling was between 1 and 2 for all sequential experiments regarding PPARα and 
LXRα.   
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Table 1. Composition of high salt PBS buffer  
  
Salt Concentration 
Sodium Chloride 150mM 
Potassium Chloride 2mM 
Sodium Phosphate (dibasic) 10mM 
Potassium Phosphate (monobasic) 1.7mM 
De-ionized water To 1L 
 
 
Prior to adding synthetic ligands, it was necessary to determine which dye-
protein combinations would be most suitable for FRET, since some may be more 
applicable than others.  Three Alexa Fluor (AF) dyes were chosen for study: AF-488, 
AF-555 and AF-594.  Preliminary control tests were completed using a fluorescently 
labeled protein in the absence of ligand, such as Alexa Fluor 488-labeled human 
LXRα (AF-488hLXRα), titrated with unlabeled protein such as hPPARα.  Similar 
tests were done for all three fluorescently labeled proteins to determine which dye-
protein combination produced a minimal change in fluorescence upon dimerization.  
This would suggest that changes seen from FRET would be a direct result of future 
ligand interaction, as opposed to natural conformational changes upon dimerization, 
caused by the extrinsic fluorophore.  The ultimate goal was to use two fluorescently 
labeled proteins, demonstrating a minimal change in fluorescence upon dimerization, 
to study the effects of a given synthetic ligand.  These studies provided valuable 
insight to protein-protein interactions in response to pharmaceutical compounds both 
on and off the market.   
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Protein-Protein Interactions in vivo 
 Direct visualization of cellular effects in vivo can provide valuable insight to 
protein-protein interactions.  This approach can be implemented using bimolecular 
fluorescence complementation (BiFC); a widely accepted technique resulting in a 
direct readout and elevated complementation signal [32].  Bimolecular fluorescence 
complementation utilizes a single fluorophore split into two parts, creating N-termal 
and C-terminal fragments [32].  These assays can be used to view intracellular effects 
in response to an added ligand, either synthetic or natural.  For example, a previous 
study utilized two fragments of the yellow fluorescent protein to study the effects of 
intracellular calcium on the M13 calmodulin binding peptide, and calmodulin itself 
[33].  By using fluorescence microscopy, this technique can be utilized to visualize 
changes in fluorescence intensity and nuclear fluorescence.  Without external ligands, 
fluorescence would likely be seen in the nucleus, however, when synthetic ligands are 
introduced, fluorescence may migrate to other parts of the cell.   
With regards to this project, in the past, the cerulean fluorescent protein (Cfp) 
was utilized to observe nuclear fluorescence upon protein-protein dimerization.  The 
N-terminal region of the Cfp protein was covalently attached to hPPARα, which was 
the central protein for this study.  Additionally, the C-terminal regions of the other 
two proteins (hLXRα and hRXRα) were covalently labeled with a mutated Cfp 
fluorophore, termed Venus and Cerulean, respectively.  Modifications of this 
fluorophore resulted in a brighter color, where resulting heterodimers produced a 
yellow signal (hLXRα-hPPARα) and a blue signal (hPPARα-hRXRα) (Figure 4).  
Additional preliminary experiments employed the same concept, except hLXRα was 
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made the central protein.  Resulting nuclear fluorescence produced a yellow color for 
hLXRα-hPPARα and a blue color for hLXRα-hRXRα.  In order for BiFC to be 
effective, it is important to know that intrinsic fluorescence is a direct result of 
protein-protein interaction and not due to the fluorophores themselves [33].  
Accordingly, it was determined that visualization of fluorescence was a direct result 
of protein-protein dimerization.  Predominantly, the goal of this technique was to 
study subcellular localization in the nucleus via fluorescence microscopy, both with 
and without synthetic ligands.  Changes in fluorescence location and intensity were 
measured, providing useful data to deepen the understanding of these nuclear 
















Figure 4.  Schematic of BiFC constructs where hPPARα is the central protein.  The N-
terminus of the Cfp protein is covalently attached to PPARα.  The C-terminal regions of 
Venus and Cerulean are covalently attached to LXRα and RXRα, respectively.  When 
PPARα and RXRα dimerize, a blue color is produced.  When LXRα and PPARα dimerize, a 
yellow color is produced.  Image Adapted from C. D. Hu and T. K. Kerppola, Nat. 
Biotechnol., 2003, 21, 539. 
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i. COS-7 Stable Transfection 
 
 Conjointly, COS-7 cells were transfected with three plasmids encoding for 
Venus-hLXRα (Figure 5A), Cerulean-hRXRα (Figure 5B), and ECFP-hPPARα 
(Figure 5C).  Stable cells were selected via antibiotic resistance, where the goal was 
to locate cells which stably integrated all three plasmids.  It is possible that some cells 
only integrated one or two plasmids, resulting in potential skewed experimental 
results when introducing ligands.  Upon the addition of ligands, it is important to 
know any changes seen in fluorescence microscopy are exclusively due to synthetic 
ligands themselves and not because plasmid integration was a temporary effect.  
Stable cells were evaluated using polymerase chain reaction (PCR) to verify the 
presence of all three plasmids.  
	  
	   	  


































Figure 5. Schematic of plasmid DNA construction for bimolecular fluorescence 
complementation using stable transfections.  (A) Plasmid pHH151 coding for VenusN172-
LXRα using the ampicillin resistance gene and a CMV promoter.  (B) Plasmid pHH152 
coding for CeruleanN172-RXR using the ampicillin resistance gene and a CMV promoter.  
(C) Plasmid pHH153 coding for ECFPC155-PPARα using the ampicillin resistance gene and 
a CMV promoter.  Plasmids were transfected into COS-7 cells resulting in stable 
transfections. 
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 ii. DNA Isolation 
Dishes of BiFC COS-7 cell clones were treated with 500 µl isolation buffer 
(100mM Tris, 1% SDS and 100mM EDTA) and DNA was isolated via chloroform 
extraction.  To isolate cellular DNA, cell lysates were treated with 1.5 µl ribonuclease 
(10 mg/ml), incubated at 42°C for 20 minutes, followed by 12 µl proteinase K (10 
mg/ml), incubated at 65°C for 30 minutes.  Subsequently, lysates were treated with 
500mM potassium acetate and allowed to chill at -20°C for 10 minutes.  Each tube 
was centrifuged at 14,000 rpm for 5 minutes and the resulting supernatant was 
collected in a fresh microcentrifuge tube.  Exactly 550 µl of Phenol:chloroform:Iso-
amyl (25:24:1) solution was added to the supernatant, mixed and centrifuged at 
14,000 rpm for 3 minutes.  Again, the supernatant was transferred to a fresh tube and 
treated with 50 µl of 300mM sodium acetate, filled to 1 ml with 100% ethanol and 
was allowed to chill at -20°C for 20 minutes.  Then, the ethanol was carefully 
removed and the DNA pellet was allowed to air dry.  Lastly, the dried DNA pellet 
was re-suspended in 40 µl of 0.1X TE (10mM tris, 1mM EDTA, pH 8.0).   
	  
iii. Polymerase Chain Reaction 
 Isolated DNA was added to GoTaq Green Master Mix (Promega) and treated 
with appropriate primers.  The primer set used for this study contained a 5’ end which 
bound to the BiFC region of the plasmid and a 3’ end which bound to the nuclear 
receptor.  Primers were designed in this fashion to ensure amplification of the nuclear 
receptor, which was covalently linked to the appropriate BiFC fragment.  
Accordingly, the DNA was denatured at 94°C while primers were allowed to anneal 
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at 58°C.  Sequentially, primer extension was completed at 72°C and the polymerase 
chain reaction process was allowed to cycle 35 times before evaluating via 
electrophoresis.  To visualize the amplified DNA of interest, resulting mixtures were 
run on a 1% Agarose gel in 0.5X TBE buffer at 150V for 45 minutes and imaged on a 
Fujifilm LAS-4000 CGR (imaging system) in the Wright State University center for 
genomics research.  Results allowed detection of cells, which contained all three 
plasmids for further in vivo studies.  
	  
iv. COS-7 Transient Transfections 
 Transient transfections were implemented due to complications with the 
stably transfected cells.  Analytical details regarding these difficulties are outlined in 
the results section.  In order to create transiently transfected cells, live COS-7 cells 
were first seeded on LabTek II chambered coverslips from 10-cm, confluent (80-
90%) dishes of wild type COS-7 cells.  Each chamber received 0.5 ml of cells and 1 
ml of fresh media (Dulbecco’s Modified Eagle Medium).  Cells were transiently 
transfected with 0.9 µl Venus-hLXRα (Figure 5A), 0.6 µl Cerulean-hRXRα (Figure 
5B), and 1.0 µl ECFP-hPPARα (Figure 5C) such that the final concentration was 700 
ng for each plasmid.  Plasmids were first combined in microcentrifuge tubes with 100 
µl serum free media and 100 µl of Lipofectamine 2000.  The tubes were allowed to 
incubate at room temperature for 30 minutes before being added to the cover slips.  
Following transfection, the cells were incubated at 37°C for 4 hours before the 
addition of ligands.  Prior to adding ligands, the media was changed to serum free so 
that ligand absorption could be claimed with high efficacy.  All ligands were re-
suspended in 50% DMSO and used at a concentration of 10µM.  Ligands used for this 
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study include ciprofibrate, fluorobexarotene and T-0901317.  After the addition of 
ligands, the cells were incubated at 37°C over night (18-20 hours).  Based on 
experimental setup, visualization of the color Venus (yellow fluorescent protein, 
YFP) indicated the presence of the heterodimer hPPARα-hLXRα and the color 
Cerulean (cyan fluorescent protein, CFP) indicated the presence of hPPARα-hRXRα. 
 A second set of experiments was completed where LXRα was the central 
partner receptor, using plasmids encoding for Venus-hPPARα (Figure 6A), ECFP-
hLXRα (Figure 6B) and Cerulean-hRXRα (Figure 5B) at volumes of 0.5 µl, 0.52 µl 
and 0.6 µl, respectively.  For this experimental set up, visualization of the color 
Venus (yellow fluorescent protein, YFP) indicated the presence of the heterodimer 
hLXRα-hPPARα and the color Cerulean (cyan fluorescent protein, CFP) indicated the 
presence of hLXRα-hRXRα.  Transfections were established using Lipofectamine 
2000, implementing the same procedure outlined above.   
	   	  






Figure 6. Schematic of plasmid DNA construction for bimolecular fluorescence 
complementation using transient transfections.  (A) Plasmid pHH203 coding for 
VenusN172-hPPARα using the ampicillin resistance gene and a CMV promoter.  (B) Plasmid 
pHH204 coding for ECFPC155-hLXRα using the ampicillin resistance gene and a CMV 
promoter.   
A B 
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v. Fluorescence Microscopy 
 Live cells were imaged using a Zeiss confocal microscope.  Sets of images 
were obtained via Axiovision software where exposures for CFP, YFP and DIC were 
set to 125 ms, 200 ms and 75 ms, respectively.  Prior to imaging, cells were rinsed 
and replenished with fresh media (Dulbecco’s Modified Eagle Medium), then 
allowed to incubate at 37°C for at least 10 minutes.  Approximately 12-15 images 










SDS-PAGE analysis demonstrated the presence of a 50kDa protein, 
corresponding to full-length, recombinant proteins used in sequential 
experiments 
 
 All experiments in this project incorporated the use of full-length recombinant 
human proteins, hLXRα, hPPARα and hRXRα, purified by affinity chromatography.  
After purification, all proteins were run separately on a 12% SDS-PAGE gel, 
indicating bands corresponding to the appropriate sizes of each nuclear receptor.  
Accordingly, each gel indicates the presence of full-length hPPARα (Figure 7A), 
hRXRα (Figure 7B) and hLXRα (Figure 7C – provided by Shimpi Bedi) around 
50kDa, consistent with the molecular weight of each protein, 52636.5Da, 51521.0Da, 
and 50807.2Da respectively.  Furthermore, hLXRα was used in combination with 
hRXRα and hPPARα to study effects of synthetic ligands, particularly evaluating the 
heterodimer hLXRα-hPPARα.  All proteins were concentrated in either PBS or Hepes 
buffer where salt concentrations were 163.7mM and 270mM, respectively.       
	  


























Figure 7.  SDS-PAGE showing purified, full-length hPPARα, hRXRα and hLXRα (A) 
12% SDS gel indicating hPPARα, where the 52kDa band corresponds with full-length 
protein, purified by affinity chromatography using a GST affinity column.  Coomassie blue 
staining was used to stain the gel, while 7.5% acetic acid was used for de-staining.  (B) 12% 
SDS gel indicating hRXRα, where the 51kDa band corresponds with full-length protein, 
purified by affinity chromatography using a GST affinity column.  Coomassie blue staining 
was used to stain the gel, while 7.5% acetic acid was used for de-staining.  (C) 12% SDS gel 
indicating hLXRα, where the 50kDa band corresponds with full-length protein, purified by 
affinity chromatography using a GST affinity column.  Coomassie blue staining was used to 
stain the gel, while 7.5% acetic acid was used for de-staining.   
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Intrinsic fluorescence quenching assays demonstrate ligand binding is not 
exclusive 
  
 Ligand binding may not be exclusive in terms of previously known 
agonistic/antagonistic properties.  Each nuclear receptor (hLXRα, hPPARα, hRXRα) 
was individually titrated with increasing amounts of synthetic ligand up to 300nM.  
Binding affinities were determined using a one-site saturation, ligand binding 
template on Sigma Plot©, where it was determined that each ligand binds with high 
affinity (Kd values in the nanomolar range).  Extensive analysis was completed for all 
eight synthetic compounds with each nuclear receptor (LXRα, RXRα and PPARα) 
individually.  Even though some compounds were previously defined as 
agonists/antagonists for certain proteins, evaluation of each ligand with each nuclear 
receptor was critical to ascertain ligand exclusivity.  This is novel data since ligand 
targets are often taken for granted without regards to the non-exclusive nature of 
these compounds.  These assumptions are a serious concern for pharmacological 
development since metabolic targets are not exclusive.  
Compounds such as auraptene, UVI 3003, GW-6471 and lovastatin 
exclusively bind their respective targets as shown with intrinsic fluorescence 
quenching (Figure 8).   However, results indicated that some compounds do not 
exclusively target one nuclear receptor as previously assumed (Figures 8 and 9).  In 
the case of fluorobexarotene, a known RXR agonist, it would seem that this 
compound preferentially binds hPPARα with a higher affinity than hRXRα (Figure 
9E and 9F).  Similar results are seen with pravastatin, classified as a hPPARα agonist, 
where binding is seen for hPPARα as well as hRXRα (Figure 8H and 8I).  This 
becomes therapeutically significant when treating patients with atherosclerosis and 
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diabetes since a given drug could have more than one target, resulting in adverse side 
effects.  Furthermore, many drugs are often pulled from the market due to negative 
side effects, potentially due to numerous, unexpected nuclear receptor targets.   
 To further evaluate protein-ligand interactions, three ligands were selected for 
further assays with the hPPARα-hLXRα heterodimer.  Fluorobexarotene was chosen 
due to its promiscuous binding to hRXRα and hPPARα, allowing for possible effects 
on both the hPPARα-hLXRα and hRXRα-hLXRα heterodimers.  Ciprofibrate was 
also chosen for further assays to evaluate the response of a hPPARα agonist on the 
hPPARα-hLXRα heterodimer, where this ligand exclusively acts through hPPARα 
(Figure 9A-C).  Lastly, compound T-0901317 was chosen as an exclusive hLXRα 
agonist, applicable for further assays with the hPPARα-hLXRα heterodimer (Figure 
9G-I).  In all cases, protein-ligand interactions are indicative of a single binding site 
based on double reciprocal plots.  
 
  










































Figure 8.  Intrinsic fluorescence quenching of hLXRα, hPPARα and hRXRα with 
synthetic ligands used in further assays.  (A-C) 100nM hLXRα, hPPARα and hRXRα, 
respectively, titrated against increasing concentrations of 0nM to 300nM auraptene.  (D-F) 
100nM hLXRα, hPPARα and hRXRα, respectively, titrated against increasing concentrations 
of 0nM to 300nM UVI-3003.  (G-I) 100nM hLXRα, hPPARα and hRXRα, respectively, 
titrated against increasing concentrations of 0nM to 300nM pravastatin.  (J-L) 100nM 
hLXRα, hPPARα and hRXRα, respectively, titrated against increasing concentrations of 0nM 
to 300nM GW-6471.  (M-O) 100nM hLXRα, hPPARα and hRXRα, respectively, titrated 
against increasing concentrations of 0nM to 300nM lovastatin.  The x-axis represents ligand 
concentration and the y-axis represents the change in fluorescence intensity for all plots.  
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Figure 9.  Intrinsic fluorescence quenching of hLXRα, hPPARα and hRXRα with 
synthetic ligands used in further assays.  (A-C) 100nM hLXRα, hPPARα and hRXRα, 
respectively, titrated against increasing concentrations of 0nM to 300nM ciprofibrate.  The x-
axis represents ciprofibrate concentration and the y-axis represents the change in fluorescence 
intensity.  (D-F) 100nM hLXRα, hPPARα and hRXRα, respectively, titrated against 
increasing concentrations of 0nM to 300nM fluorobexarotene.  The x-axis represents 
fluorobexarotene concentration and the y-axis represents the change in fluorescence intensity.  
(G-I) 100nM hLXRα, hPPARα and hRXRα, respectively, titrated against increasing 
concentrations of 0nM to 300nM T-0901317.  The x-axis represents T-0901317 concentration 
and the y-axis represents the change in fluorescence intensity.  Insets represent double 
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Table 2. Intrinsic fluorescence quenching of 100nM hLXRα, hPPARα and hRXRα 
titrated with synthetic ligands (100µM).  
  
Synthetic Compound Kd (hLXRα) (nM) Kd (hPPARα) (nM) Kd (hRXRα) (nM) 
Ciprofibrate ND 2.5 ± 0.8 ND 
Fluorobexarotene ND 6.0 ± 3.0 18.0 ± 5.0 
T-0901317 4.0 ± 1.0 ND ND 
ND = Not determinable  
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Synthetic ligands induce changes in the secondary structure of the hPPARα-
hLXRα heterodimer 
 
 Circular dichroism was used to visualize changes in secondary structure of the 
novel heterodimer hLXRα-hPPARα in response to synthetic ligands.  This technique 
utilizes left and right circularly polarized light to generate differential absorption 
spectra.  The circular dichroism experiment required the use of full-length hPPARα 
and hLXRα, in addition to synthetic ligands solubilized in DMSO or ethanol at a 
concentration of 5µM.  
Characteristically, in the absence of ligand, the circular dichroic spectra of 
hLXRα-hPPARα demonstrates a positive peak around 190nm and two negative peaks 
around 210-220nm (Figure 10).  Accordingly, this is indicative of an alpha-helical 
structure, consistent with previous data [29].  When ciprofibrate and fluorobexarotene 
are introduced, the spectra become slightly distorted, reducing the estimate of alpha 
helical content (Figure 10A and 10B).  This finding was confirmed upon 
computational and statistical analysis of percent composition regarding regular and 
distorted α-helices, β-sheets, turns and unordered structures using Sigma Plot©.  
Fluorobexarotene induced conformational changes in the secondary structure of 
hLXRα-hPPARα, particularly regarding turns where the p value was <0.06 (Table 3).  
Ciprofibrate demonstrated variations in the estimated α-helices and turns of the 
hLXRα-hPPARα heterodimer where p values were <0.0001 and <0.01, respectively 
(Table 3).  On the other hand, it would appear T-0901317 induces conformational 
changes consistent with an increase in estimated alpha-helical content (Figure 10C).  
This result was further confirmed by structural analysis where both regular and 
distorted α-helices, β-sheets and turns yielded p values of <0.0001 (Table 3), 
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suggesting T-0901317 has a significant effect on the secondary structure of hLXRα-
hPPARα.  This would indicate that these synthetic ligands could significantly alter 
secondary structure of the heterodimer hLXRα-hPPARα, as a whole, potentially 
affecting unforeseen metabolic targets in therapeutic medicine.   
  















Figure 10. Circular Dichroic spectra of a mixture of hPPARα and hLXRα in the 
presence and absence of synthetic ligands.  (A) Far-UV spectra of a mixture of equal amino 
acid molarities of hPPARα and hLXRα in the absence (open circles) and presence (closed 
circles) of 5µM fluorobexarotene.  (B) Far-UV spectra of a mixture of equal amino acid 
molarities of hPPARα and hLXRα in the absence (open circles) and presence (closed circles) 
of 5µM ciprofibrate.  (C) Far-UV spectra of a mixture of equal amino acid molarities of 
hPPARα and hLXRα in the absence (closed circles) and presence (open circles) of 5µM T-
0901317.  Each spectrum is composed of an average of ten scans, taken from three replicates.   
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Table 3.  Secondary structures of hPPARα and hLXRα (corrected for solvent effect) 



















DMSO 24.5 ± 0.5 20.5 ± 3.5 12.0 ± 2.0 14.5 ± 0.5 11.5 ± 0.5 16.5 ± 0.5 
Ethanol 21.4 ± 0.6 14.9 ± 0.4 8.5 ± 0.2 6.9 ± 0.1 17.1 ± 0.2 31.3 ± 0.8 
Fluorobexarotene 23.3 ± 1.3 21.3 ± 1.5 12.0 ± 1.1 15.3 ± 0.3 14.3 ± 0.7* 15.0 ± 1.5 
Ciprofibrate 20.7 ± 0.7*** 19.3 ± 0.9 13.3 ± 1.2 16.0 ± 0.6 17.0 ± 0.6** 14.0 ± 1.0 
T-0901317 15.6 ± 0.8*** 12.6 ± 0.3*** 11.5 ± 0.7*** 8.4 ± 0.3*** 20.1 ± 0.2*** 31.8 ± 0.5 
Asterisks (*) represent significant differences due to presence of ligand as compared with the absence 
of ligand for all panels. *p = <0.06, **p = <0.01, ***p = <0.0001. 
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Alexa Fluor dyes 488 and 555 are optimal for fluorescence resonance energy 
transfer (FRET) experiments 
	  
	  
	   Fluorescence resonance energy transfer allows for the visualization of energy 
transfer between two fluorescently labeled molecules.  This experiment utilizes Alexa 
Fluor (AF) dyes, as opposed to Cy3 and Cy5 dyes, due to enhanced environmental 
stability.  Even so, certain dye-protein combinations may not be favorable in terms of 
FRET.  Ideally, the chosen fluorophore would yield minimal changes in fluorescence 
when titrated with the unlabeled molecule of interest.  Confirmation of this 
phenomenon required preliminary tests where each protein was labeled with a certain 
Alexa Fluor dye and titrated with an unlabeled partner receptor.   
	   Based on experimental results, hPPARα labeled with AF-555 was an ideal 
dye-protein combination for FRET, where hRXRα was the partner receptor (Figure 
11A).  When AF-555hPPARα was titrated against unlabeled hRXRα there were 
minimal changes in fluorescence, suggesting AF-555hPPARα is a useful candidate 
for FRET.  While this dye-protein combination seems promising, the novel 
heterodimer hPPARα-hLXRα is the point of interest.  The same preliminary 
experiment was completed for AF-555hPPARα titrated against unlabeled hLXRα, yet 
this yielded changes in fluorescence upon dimerization (Figure 11B).  Similar 
experiments were implemented for AF-555hRXRα, however, changes in fluorescence 
were visualized upon dimerization with both hLXRα and hRXRα (Figure 11C and 
11D).  Since AF-555hPPARα showed the most environmental stability when titrated 
against unlabeled hRXRα, this dye-protein combination is favorable for FRET.   
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 Similarly, spectra for AF-488hLXRα, titrated with increasing amounts of 
either unlabeled hRXRα or hPPARα (Figure 12A and 12B), demonstrated a minimal 
change in fluorescence, suggesting AF-488hLXRα is an ideal dye-protein 
combination for further FRET experiments.  Alexa Fluor 488-hPPARα would also be 
an acceptable dye-protein combination since changes in fluorescence were minimal 
(Figure 12C and 12D).  However, when Alexa Fluor dye 488 was used to label 
hRXRα, changes in fluorescence were visualized upon titration against unlabeled 
partner receptors, suggesting AF-488hRXRα is not optimal for FRET (Figure 12E 
and 12F).   
 Lastly, Alexa Fluor dye 594 was examined in a similar fashion where AF-
594hRXRα was titrated against unlabeled hLXRα and hPPARα (Figure 13A and 13B, 
respectively).  Unfortunately, changes in fluorescence were visualized upon 
dimerization, indicating Alexa Fluor dye 594 may be problematic for FRET.  The 
nature of extrinsic fluorophores is not concrete and environmental stability may still 
be a factor.  Based on experimental results and available resources, AF-488hLXRα 
was chosen as the donor and AF-555hPPARα was chosen as the acceptor for further 




	   	  




























Figure 11. Fluorescent binding assays using Alexa Fluor (AF) 555-labeled protein, 
titrated against increasing concentrations of unlabeled protein.  (A) 25nM of AF-
555hPPARα was titrated against increasing concentrations of 0nM to 250nM hRXRα.  The x-
axis indicates the concentration of the titrant, hRXRα, while the y-axis represents changes in 
fluorescence intensity.  (B) 25nM of AF-555hPPARα was titrated against increasing 
concentrations of 0nM to 250nM hLXRα.  The x-axis indicates the concentration of hLXRα, 
while the y-axis represents changes in fluorescence intensity.  (C) 25nM of AF-555hRXRα 
was titrated against increasing concentrations of 0nM to 250nM hLXRα.  The x-axis indicates 
the concentration of hLXRα, while the y-axis represents changes in fluorescence intensity.  
(D) 25nM of AF-555hRXRα was titrated against increasing concentrations of 0nM to 250nM 
hPPARα.  The x-axis indicates the concentration of hPPARα, while the y-axis represents 
changes in fluorescence intensity.  Insets represent double reciprocal plots.      
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Figure 12. Fluorescent binding assays using Alexa Fluor (AF) 488-labeled protein, 
titrated against increasing concentrations of unlabeled protein.  (A) 25nM of AF-
488hLXRα was titrated against increasing concentrations of 0nM to 250nM hRXRα.  The x-
axis indicates the concentration of the titrant, hRXRα, while the y-axis represents changes in 
fluorescence intensity.  (B) 25nM of AF-488hLXRα was titrated against increasing 
concentrations of 0nM to 250nM hPPARα.  The x-axis indicates the concentration of 
hPPARα, while the y-axis represents changes in fluorescence intensity.  (C) 25nM of AF-
488hPPARα was titrated against increasing concentrations of 0nM to 250nM hRXRα.  The x-
axis indicates the concentration of hRXRα, while the y-axis represents changes in 
fluorescence intensity.  (D) 25nM of AF-488hPPARα was titrated against increasing 
concentrations of 0nM to 250nM hLXRα.  The x-axis indicates the concentration of hLXRα, 
while the y-axis represents changes in fluorescence intensity.  (E) 25nM of AF-488hRXRα 
was titrated against increasing concentrations of 0nM to 250nM hLXRα.  The x-axis indicates 
the concentration of hLXRα, while the y-axis represents changes in fluorescence intensity.  
(F) 25nM of AF-488hRXRα was titrated against increasing concentrations of 0nM to 250nM 
hPPARα.  The x-axis indicates the concentration of hPPARα, while the y-axis represents 
changes in fluorescence intensity.  Insets represent double reciprocal plots. 
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Figure 13. Fluorescent binding assays using Alexa Fluor (AF) 594-labeled protein, 
titrated against increasing concentrations of unlabeled protein.  (A) 25nM of AF-
594hRXRα was titrated against increasing concentrations of 0nM to 150nM hLXRα.  The x-
axis indicates the concentration of the titrant, hLXRα, while the y-axis represents changes in 
fluorescence intensity.  (B) 25nM of AF-594hRXRα was titrated against increasing 
concentrations of 0nM to 150nM hPPARα.  The x-axis indicates the concentration of 
hPPARα, while the y-axis represents changes in fluorescence intensity.   
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Nuclear receptors hPPARα and hLXRα bind with high affinity, as shown by 
FRET 
 
 Characteristically, when two proteins dimerize, energy transfer can be 
visualized via FRET where there is a decrease in donor emission, with a concomitant 
increase in acceptor emission when excited at the proper wavelength.  When AF-
488hLXRα is titrated against AF-555hPPARα, the raw spectrum depicts the 
occurrence of FRET, indicated by a decrease in donor emission around 520nm and an 
increase in acceptor emission around 565nm (Figure 14A).  Either the donor or 
acceptor peaks can be used to generate a binding curve where binding affinity can be 
quantified.  Based on this quantitative assay using peak values from quenching, 
hPPARα and hLXRα exhibit a binding affinity of 8 ± 3 nM (Figure 14B).  Biological 
effects of this novel heterodimer are still being studied, however, knowledge of this 
interaction could benefit diseases such as atherosclerosis and diabetes.  In particular, 
effects of synthetic ligands on this heterodimer would be beneficial in demonstrating 
pharmacological effects on a cellular level.   
 A similar experiment was performed with AF-488hLXRα and AF-555hRXRα 
to verify that this technique is effective.  Subsequently, FRET was observed via a 
decrease in donor emission around 520nm and an increase in acceptor emission 
around 565nm (Supplemental Figure 2A).  A binding curve was generated from the 
emission data, confirming hLXRα and hRXRα bind with high affinity (Supplemental 
Figure 2B).  This solidifies the knowledge that FRET is an accurate measure of 
affinity with regards to nuclear receptors.  
  















Figure 14. FRET using AF-488hLXRα as the donor and AF-555hPPARα as the 
acceptor. 
(A) 25nM AF-488hLXRα titrated against increasing concentrations of 0nM to 100nM AF-
555hPPARα.  The x-axis represents wavelength (nm) and the y-axis depicts fluorescence 
intensity.  Excitation wavelength was set at 488nm and emission scans were collected over a 
range of 500-667nm.  (B) 25nM AF-488hLXRα titrated against increasing concentrations of 
0nM to 100nM AF-555hPPARα.  The x-axis indicates the concentration of AF-555hPPARα 
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Synthetic ligands have an effect on the binding affinity of hLXRα and hPPARα 
 
 
 The effects of synthetic ligands on the novel heterodimer, hLXRα-hPPARα, 
could provide valuable insight into therapeutic medicine.  Cholesterol and diabetic 
drugs are often pulled from the market due to increasingly negative side effects in 
humans.  The hLXRα-hPPARα heterodimer is a key component of cholesterol 
homeostasis and metabolic pathways, where knowledge of cellular interactions could 
provide valuable insight to therapeutic medicine.  Fluorescence resonance energy 
transfer experiments demonstrate ciprofibrate and T-0901317 increase the Kd value of 
the hLXRα-hPPARα heterodimer to 11 ± 2nM and 10 ± 2nM, respectively (Figure 
15A and 15B).  When similar energy transfer experiments were done with 
fluorobexarotene, the Kd value decreased to 5 ± 1nM (Figure 15C), suggesting 
fluorobexarotene enhances the binding affinity between hLXRα and hPPARα.  This 
data may be therapeutically significant since a known RXR agonist induces a change 
in dimerization of hLXRα-hPPARα, possibly providing an explanation for negative 
side effects, such as increased triglycerides, often associated with cholesterol and 




	   	  
















Figure 15. FRET using AF-488hLXRα as the donor and AF-555hPPARα as the 
acceptor in the presence of synthetic ligands.  (A) 25nM AF-488hLXRα titrated against 
increasing concentrations of 0nM to 75nM AF-555hPPARα in the presence of 6nM 
ciprofibrate.  The x-axis indicates the concentration of AF-555hPPARα and the y-axis 
represents changes in fluorescence intensity.  (B) 25nM AF-488hLXRα titrated against 
increasing concentrations of 0nM to 100nM AF-555hPPARα in the presence of 10nM T-
0901317.  The x-axis indicates the concentration of AF-555hPPARα and the y-axis represents 
changes in fluorescence intensity.  (C) 25nM AF-488hLXRα titrated against increasing 
concentrations of 0nM to 100nM AF-555hPPARα in the presence of 13nM fluorobexarotene.  
The x-axis indicates the concentration of AF-555hPPARα and the y-axis represents changes 
in fluorescence intensity. 
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Table 4. Fluorescence resonance energy transfer of 25nM AF-488hLXRα titrated 
against AF-555hPPARα over a range of 0nM to 100nM in the presence and absence 
of synthetic ligands.  
 
Synthetic Compound Kd (hLXRα-hPPARα) (nM) 
No ligand 8 ± 3 
Ciprofibrate 11 ± 2 
Fluorobexarotene 5 ± 1 
T-0901317 10 ± 2 
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Stably transfected COS-7 cells contain all three nuclear receptor plasmids, as 
shown with PCR testing 
 
 Stable COS-7 BiFC clones were analyzed via PCR to verify the presence of 
all three nuclear receptor plasmids.  Stable COS-7 cells used in this project were 
engineered by Heather Hostetler, PhD and S. Dean Rider, Jr., PhD.  The original goal 
was to verify the presence of all three nuclear receptors in these cells before treating 
with synthetic ligands.  It is possible that some COS-7 clones created in this fashion, 
did not integrate and express all three nuclear receptors.  Therefore, it was important 
to solidify the presence of all plasmids to ensure that future effects seen with 
synthetic ligands were valid.   
 Initially, the use of stably transfected cells were preferable because it would 
be possible to ensure complete integration of the appropriate nuclear receptor into the 
cell’s genome, where genetic information would be passed on to future generations.  
Accordingly, effects seen by an added nutrient or ligand would be uncontested.  Out 
of 49 COS-7 clones analyzed, 15 indicated successful integration of all three proteins 
and were further used in fluorescence microscopy studies (Figure 16).     
	   	  












Figure 16. Electrophoresis showing the presence of nuclear receptor plasmids in COS-7, 
stably transfected cells.  (A) 1% agarose gel showing the presence of the hLXRα plasmid 
(350 base pairs), isolated by DNA chloroform extraction and evaluated using PCR.  (B) 1% 
agarose gel showing the presence of the hPPARα plasmid (312 base pairs), isolated by DNA 
chloroform extraction and evaluated by PCR.  (C) 1% agarose gel showing the presence of 
the hRXRα plasmid (678 base pairs), isolated by DNA chloroform extraction and evaluated 
by PCR. 
WT – wild type COS-7 cells (no transfection), bp – base pairs, PCR – polymerase chain 
reaction 
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BiFC quantitative analysis indicates variation in subcellular localization of 
transiently transfected COS-7 cells, in response to synthetic ligands 
 
 
 Fluorescence microscopy was utilized to visualize changes in fluorescence 
intensity and subcellular localization in COS-7 cells.  Initially, stably transfected cells 
were utilized to ensure the presence of all three nuclear receptors before the addition 
of ligands.  Fluorescence microscopy was used to analyze these cells in the absence 
of ligand to ascertain a baseline for sequential experiments, where ligands would be 
tested for their ability to alter heterodimer formation.  Ideally, transfected cells would 
exhibit nuclear fluorescence, with an absence of fluorescence seen in un-transfected 
COS-7 cells.  Resulting fluorescent images that were obtained from the stably 
transfected cells were difficult to analyze due to punctuate fluorescence in both CFP 
and YFP (Figure 17).  This anomaly could be attributed to variations dependent on 
cell cycle.  As a result, quantitative analysis was unattainable for these images and 
future experiments employed the use of transient transfections. 
 Transient transfections of COS-7 cells displayed nuclear fluorescence which 
allowed for further quantitative analysis via ImageJ© software.  Fluorescence 
microscopy indicated nuclear fluorescence for most of the transfected cells in the 
presence and absence of synthetic ligand (Figure 18).  In this case, “wild type” refers 
to transfected cells in the absence of ligand, where resulting fluorescent images could 
be used as a baseline for ligand comparisons.  Analysis of fluorescence intensity and 
co-localization were compared to wild type images to understand in vivo effects of 
synthetic ligands. 
	   68 
Quantitative analysis of transiently transfected COS-7 cells focused on 
variations in fluorescence intensity and subcellular localization.  The experiment was 
set up such that ECFP-hPPARα was the central receptor while Cerulean-hRXRα and 
Venus-hLXRα were the partner receptors.  In this case, resulting fluorescent images 
would display hPPARα-hLXRα interaction as yellow and hPPARα-hRXRα 
interaction as cerulean (blue).  Analysis of fluorescence intensity utilized numerical 
values, tabulated from corrected total cell fluorescence (CTCF).  Results indicated 
nearly parallel lines when CTCF was plotted against Kd values, previously 
determined from FRET (Figure 19A).  This would suggest fluorescence intensity is 
nearly the same across all experimental compounds, directing us to use overlap R for 
co-localization analysis.  This particular variable, R, is representative of subcellular 
localization in the nucleus, which does not incorporate pixel averaging.  Therefore, 
the resulting value would be between 0 and 1 and would be insensitive to intensity 
variations.  This is preferable when compared to Pearson’s coefficient, which also 
evaluates the extent of overlap between two images, because variations in pixel 
intensity would present a misleading readout.  Accordingly, quantitation of nuclear 
co-localization yielded numerical values between 0 and 1 where wild type cells 
presented a R value of 0.9894, while synthetic compounds ciprofibrate, 
fluorobexarotene and T-0901317, yielded R values of 0.9858, 0.9899 and 0.9819, 
respectively (Figure 19B).  While these changes are seemingly small and yield no 
statistical significance, the fact that changes are seen should be noted.  Furthermore, it 
would seem that co-localization (R) shows a decreasing trend with increasing Kd 
values.  The Kd values plotted in this fashion represent binding affinities for the 
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hPPARα-hLXRα heterodimer, however, evaluation with synthetic ligands could have 
unanticipated effects on the hPPARα-hRXRα heterodimer.  This could be important 
when treating human patients with synthetic compounds since desired outcomes may 
not be exclusive, resulting in unforeseen side effects.  
An additional experiment was completed where ECFP-hLXRα was made to 
be the central receptor, while the partner receptors were Cerulean-hRXRα and Venus-
hPPARα.  In this case, dimerization of hLXRα-hRXRα would result in a cerulean 
color and hLXRα-hPPARα would produce a yellow color.  Similar analysis of 
fluorescence intensity and co-localization were established in sequential experiments, 
evaluating the presence of hLXRα-hPPARα and hLXRα-hRXRα in the cell nucleus 
(Supplemental Figures 4A and 4B).  The anomaly in this data is treatment with T-
0901317, which can potentially affect both heterodimers, adding another layer of 
complication since Kd values used for co-localization plots are for hPPARα-hLXRα.  
Even so, co-localization analysis in this case displays no significant changes when 
compared to Kd values of hLXRα-hPPARα (Supplemental Figure 4B).  It should be 
noted that results from this experiment are not comparable to the previous 
experiments where hPPARα was the central receptor since this experiment utilizes 




	   	  










Figure 17. Fluorescence microscopy of stably transfected COS-7 cells in the absence of 
ligand.  (A) CFP in three COS-7 cells.  (B) YFP in three COS-7 cells.  (C) Overlay of CFP 
and YFP in three COS-7 cells.  (D) DIC image with an overlay of CFP and YFP in three 
COS-7 cells.  Visualization of these cells indicates healthy growing conditions. 
	  
	   	  












Figure 18.  Fluorescence microscopy indicates nuclear fluorescence for all transiently 
transfected COS-7 cells, in the absence and presence of synthetic ligand.  (A-B) CFP and 
YFP, respectively, in wild type COS-7 cells, in the absence of synthetic ligand.  Cyan is 
indicative of hPPARα-hRXRα and yellow is indicative of hPPARα-hLXRα.  (C-D) CFP and 
YFP, respectively, in COS-7 cells in the presence of 10µM fluorobexarotene.  Cyan is 
indicative of hPPARα-hRXRα and yellow is indicative of hPPARα-hLXRα.  (E-F) CFP and 
YFP, respectively, in COS-7 cells in the presence of 10µM ciprofibrate.  Cyan is indicative of 
hPPARα-hRXRα and yellow is indicative of hPPARα-hLXRα.  (H-I) CFP and YFP, 
respectively, in COS-7 cells in the presence of 10µM T-0901317.  Cyan is indicative of 
hPPARα-hRXRα and yellow is indicative of hPPARα-hLXRα.	  
	  
	   	  











Figure 19.  Quantitative analysis of transiently transfected COS-7 cells in response to 
synthetic ligands where ECFP-hPPARα is the central partner receptor.  (A) 
Fluorescence intensity for CFP and YFP in the absence and presence of synthetic ligands.  
The x-axis indicates Kd values for the hPPARα-hLXRα heterodimer, previously determined 
from FRET in the absence and presence of ciprofibrate, fluorobexarotene and T-0901317.  
The y-axis indicates the average corrected total cell fluorescence (CTCF) for both CFP and 
YFP.  (B) Co-localization of hLXRα and hPPARα in COS-7 cell nuclei in the absence and 
present of synthetic ligands.  The x-axis indicates Kd values for the hPPARα-hLXRα 
heterodimer, previously determined from FRET in the absence and presence of ciprofibrate, 
fluorobexarotene and T-0901317.  The y-axis indicates co-localization overlap, R, which is 




























































Diseases such as atherosclerosis and diabetes result from a host of metabolic 
abnormalities linked to obesity.  Misregulation of homeostatic pathways leads to a 
constellation of metabolic syndromes, affecting fatty acid and cholesterol metabolism 
[2].  Regulatory proteins such as PPAR and LXR are targeted for therapeutic study, 
where an exclusive pharmacological profile is contested.  For example, fibrate 
compounds have been implemented in multiple studies to further characterize the role 
of PPARα where it has been shown that PPARα activation by fibrates has beneficial 
effects on lipid metabolism [4].  Fibrates target PPARα, inducing an increase in fatty 
acid oxidation and glucose sparing in the heart and liver, providing beneficial effects 
such as decreased lipid accumulation as a result of increased HDL’s [4].  However, 
negative side effects often result in increased triglycerides and weight gain [4].  These 
negative effects could be attributed to another nuclear receptor such as LXR.  As with 
any pharmacological profile, side effects are a rising issue where a PPAR drug could 
potentially induce an LXR effect, or visa versa, suggesting unanticipated outcomes 
resulting in dangerous side effects.  The primary goal would be to develop or discover 
a synthetic ligand that would exclusively target a single homeostatic pathway.  
Synthetic ligands examined in this study presented novel protein-ligand binding 
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properties, providing a possible explanation for negative side effects in therapeutic 
use.     
 To effectively study synthetic ligands and their application to human use, it is 
necessary to generate full-length human proteins for all experiments.  Prior 
experiments in the lab demonstrated that truncated and full-length forms of these 
nuclear receptor proteins behave differently.  All full-length proteins were purified 
using affinity chromatography and evaluated via SDS-PAGE, confirming the 
presence of the desired protein around 50kDa.  The use of full-length human proteins 
bridges the gap between in vitro and in vivo assays, allowing generation of data 
applicable to human diagnosis.  While in vivo assays are still necessary, data 
generated in vitro can still provide valuable insight into therapeutic medicine, further 
aiding in understanding of diseases linked to atherosclerosis and diabetes. 
 Ligand binding becomes increasingly complicated as nuclear receptors, LXR 
and PPAR, form obligate heterodimers with RXR [16].  More recently, it has been 
shown that LXR can dimerize with PPAR, presenting a novel heterodimer exhibiting 
cross talk, where ligands can influence heterodimer choice [16, 29].  Of the 
compounds evaluated in this project, ciprofibrate and T-0901317 exhibited exclusive 
binding characteristics for PPARα and LXRα, respectively.  Interestingly, 
fluorobexarotene, a known RXR agonist, demonstrated promiscuous binding to 
PPARα, suggesting that previously assumed ligand binding characteristics are not 
always predictable.  This finding could possibly account for negative side effects seen 
with many pharmaceutical compounds on the market.  Therefore, these three 
compounds were selected for further study regarding the PPARα-LXRα heterodimer.   
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 The secondary structure of a given protein ensures proper function and 
directly affects ligand-binding, linking secondary structure to metabolic function.  
Typically, ligand binding induces changes in secondary structure, characterizing 
ligand-regulated nuclear transcription factors such as PPAR, LXR and RXR [5].  
Subsequently, alterations to protein secondary structure can significantly alter the 
functionality of a given protein.  Likewise, conformational changes, induced by 
synthetic ligands, become significant in characterizing protein function, relevant to 
therapeutic medicine.  
This study employed the use of circular dichroism to evaluate the 
heterodimeric structure of hPPARα-hLXRα in response to synthetic ligands.  In the 
absence of ligand, it was confirmed that the hPPARα-hLXRα heterodimer is 
composed of numerous alpha helices, characterized by the circular dichroic spectra.  
While all three ligands demonstrated changes in heterodimer conformation, 
compound T-0901317 induced the most significant changes in the alpha-helical 
nature of the hPPARα-hLXRα heterodimer.  Understanding how certain ligands 
affect protein secondary structure can provide enhanced understanding of 
heterodimeric function in metabolism, and its tandem use in therapeutic medicine.  
 Since ligand binding can affect protein secondary structure, effectively 
altering metabolic function, another level of complexity arises where protein-protein 
interactions could be affected.  It is possible that the binding affinity of hPPARα for 
hLXRα could be altered in the presence of synthetic ligands, presenting possible 
repercussions when using pharmaceuticals for therapeutic treatment.  It then becomes 
necessary to evaluate protein-protein interactions in the presence of synthetic ligands 
	   76 
to further understand the intricate nature of this novel heterodimer and its role in 
cholesterol metabolism.  Fluorescence resonance energy transfer was used to 
determine the effects of synthetic compounds on the hPPARα-hLXRα heterodimer.   
Based on preliminary testing, it was determined that Alexa Fluor dye 488 and 
555 would be best suitable for these experiments where AF-488hLXRα was termed 
the donor and AF-555hPPARα was termed the acceptor.  During energy transfer, a 
noticeable decrease was seen in donor emission, followed by an increase in acceptor 
emission, when excited at the proper wavelength.  Further evaluation of changes in 
fluorescence allows a binding curve to be generated, where binding affinities can be 
assessed.  In the absence of ligand, the hPPARα-hLXRα heterodimer exhibited a Kd 
value of 8 ± 3 nM.  When ligands such as ciprofibrate and T-0901317 were 
introduced, there was an apparent increase in the Kd value, 11 ± 2 nM and 10 ± 2 nM, 
respectively.  This data would suggest that ciprofibrate and T-0901317 induce protein 
conformational changes that effectively decrease affinity of hLXRα for hPPARα.  On 
the other hand, fluorobexarotene appeared to enhance binding affinity of hLXRα for 
hPPARα, presenting a Kd value of 5 ± 1 nM.  This data presents valuable 
understanding of how synthetic ligands directly affect protein-protein binding, further 
linking ligand exclusivity to negative side effects in therapeutic use.   
 The next step was to evaluate these nuclear receptors in vivo by using 
bimolecular fluorescence complementation (BiFC) and live cell imaging.  Initially, 
stably transfected COS-7 cells were desirable due to genomic plasmid integration.  
These cells were selected by antibiotic resistance and further analyzed by polymerase 
chain reaction to ensure complete integration of all three nuclear receptor plasmids.  
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Isolated cellular DNA was evaluated by electrophoresis, yielding bands at 350, 678 
and 312 base pairs, indicating the presence of hLXRα, hRXRα and hPPARα, 
respectively.  While these results were promising, further fluorescence microscopy 
experiments, employing the use of stably transfected cells, yielded limited success.  
Resulting cell images displayed punctuate fluorescence, often in vesicles surrounding 
the nucleus, however, no nuclear fluorescence was seen.  Therefore, transient 
transfections were used to characterize the effects of synthetic ligands. 
 Accordingly, after transient transfections with the appropriate BiFC plasmids, 
nuclear localization was visualized in COS-7 cells via fluorescence microscopy.  
Unlike the stable transfections, these fluorescent images demonstrated distinct nuclear 
fluorescence, in accordance with the anticipated heterodimeric outcomes.  All 
fluorescent microscopy images displayed a more intense CFP color than YFP, where 
this phenomenon could be attributed to several possible reasons.  First, it is possible 
that there are simply fewer binding sites for hLXRα-hPPARα in the COS-7 cell 
genome than hPPARα-hRXRα.  Yet this is highly unlikely due to the use of equal 
plasmid amounts in transfections.  Secondly, CFP has a higher quantum yield than 
YFP, meaning the ratio of photons absorbed to photons emitted is much higher for 
CFP, resulting in a brighter signal.  The later point becomes significant when 
analyzing subcellular localization since pixel overlap between images can be affected 
by this phenomenon.  Accordingly, the overlap coefficient, R, was used for co-
localization quantitation since it is characterized by pixel correlations, insensitive to 
fluorescence intensity.   
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 To correct for variations seen in fluorescence intensity, images were analyzed 
by correcting for total cell fluorescence, using measurements of integrated density, 
area of selected cells and the mean fluorescence of background readings.  After total 
cell fluorescence was corrected, quantitative analysis yielded minimal variations in 
fluorescence intensity in response to synthetic ligands.  Logically, it could be 
assumed that a ligand, which inhibits or lessens the binding affinity of hPPARα-
hLXRα, would result in a decreased yellow signal.  Presumably, such would be the 
case for ciprofibrate and T-0901317, however, it is possible that the cell’s response is 
to compensate for this “inhibition” by producing more hPPARα and hLXRα.  This 
phenomenon would effectively mask any effects seen with fluorescence intensity, 
which could explain the minimal changes in fluorescence intensity.  Subsequently, 
the use of the co-localization overlap, R, becomes necessary for further evaluation.   
When the overlap coefficient, R, is plotted against previously determined Kd 
values from FRET, a small trend emerges.  It would seem that co-localization 
decreases as the Kd value increases.  Co-localization, in this case, is evaluating the 
presence of two heterodimers, hPPARα-hLXRα and hPPARα-hRXRα, in the nucleus.  
The binding affinity values are only for hLXRα-hPPARα, therefore, synthetic ligands 
could have unforeseen effects on hRXRα-hPPARα localization.  This is especially 
plausible since ligand binding was shown to be non-exclusive in the case of 
fluorobexarotene.  This experiment was performed twice, producing similar results in 
each case (Supplemental Figure 3A and 3B).   
If certain ligands affect hLXRα-hPPARα binding, the cell could attempt to 
compensate for this effect by making more protein, effectively masking variations in 
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fluorescence intensity or co-localization.  Based on results established from intrinsic 
fluorescence quenching and FRET assays, we would anticipate seeing some kind of 
change in fluorescence intensity or co-localization with the addition of a synthetic 
ligand.  The results achieved with BiFC did not produce the desired outcome with 
synthetic ligands for several variable factors.  First, there are distinct differences 
between proteins evaluated in a cuvette versus a living cell.  Secondly, the in vitro 
assays were performed under conditions where the reaction between PPARα and 
LXRα was reversible; therefore, the binding affinity (Kd) value was significant.  The 
BiFC experiments required a covalent link between the two proteins of interest 
(PPARα and LXRα) due to the nature of the fluorophores.  In this case, the resulting 
reaction between the two proteins was irreversible and the relevancy of binding 
affinity (Kd) between PPARα and LXRα in the presence of synthetic ligands becomes 
questionable.  Third, there are distinct differences in the amount of protein utilized 
during in vivo and in vitro assays. The CMV promoter used in the experiment is a 
strong viral promoter and produces high levels of receptors (unlike the native 
promoters would) and this high level of protein may be too high for this experiment 
to reveal the differences we anticipated. The high protein levels in a living cell could 
explain the small changes in co-localization. Alternative methods for regulating 
protein levels in the cell may allow us to reveal the differences in vivo that were 
observed in vitro.  
 In conclusion, this project has demonstrated novel properties of ligand 
binding, secondary structures, protein-protein interactions and in vivo effects, relevant 
to the therapeutic treatment of diseases associated with obesity and diabetes.  
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Understanding how current pharmaceuticals affect nuclear receptors in the human 
body, can lead to a better platform to assess a host of diseases associated with 
diabetes.  Diseases such as atherosclerosis, hypertriglyceridemia, hypertension and 
insulin resistance could benefit from this research.  Intricate knowledge of cholesterol 
and fatty acid metabolism can help scientists further develop drugs to accurately 
balance metabolic homeostasis, potentially minimizing negative side effects for 
therapeutic application.      
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VI. LIST OF ABREVIATIONS 
ABC - ATP binding cassette 
ACOX1 - peroxisomal acyl-coenzyme A oxidase 
Apo – apolipoprotein 
ChREBP - cholesterol regulatory element binding protein 
CYP7A1 - cholesterol 7α-hydroxylase 
FABP1 - fatty acid binding protein 1 
FAS – fatty acid synthase 
FDA – Federal drug administration 
HDL - high-density lipoprotein 
HMG-CoA - 3-hydroxy-3-methylglutaryl-coenzyme A 
HNF4A – hepatocyte nuclear factor 4 alpha 
IPTG – isopropyl β-D-1-thiogalactopyranoside 
LB – Luria Bertani media 
LBD – ligand binding domain 
LPL - lipoprotein lipase 
LXR – liver X receptor 
N-CoR – nuclear co-repressor 
PMSF – phenylmethylsulfonyl fluoride 
PPAR – peroxisome proliferator-activated receptor
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PPRE - peroxisome proliferator response element 
RXRE – retinoid X receptor response element  
RXR – retinoid X receptor 
SMRT – silencing mediator for retinoid and thyroid hormone receptors 
SPR – surface plasmon resonance 
SREBP-1 - sterol regulatory element-binding protein 
TGFB – transforming growth factor beta 
UCP – uncoupling protein 
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Supplemental Table 1. Intrinsic fluorescence quenching of 100nM hLXRα, hPPARα 
and hRXRα titrated with synthetic ligands (100µM).  
  
Synthetic Compound Kd (hLXRα) (nM) Kd (hPPARα) (nM) Kd (hRXRα) (nM) 
Auraptene ND 5.0 ± 3.0 ND 
GW 6471 7.0 ± 4.0 67.0 ± 31.0 ND 
Lovastatin ND 0.6 ± 0.5 ND 
Pravastatin ND 1.0 ± 1.0 20.0 ± 9.0 
UVI 3003 ND ND 10.0 ± 2.0 
































Supplemental Figure 1. Circular Dichroic spectra of a mixture of hPPARα and hLXRα 
in the presence and absence of synthetic ligands.  (A) Far-UV spectra of a mixture of equal 
amino acid molarities of hPPARα and hLXRα in the absence (open circles) and presence 
(closed circles) of 5µM auraptene.  (B) Far-UV spectra of a mixture of equal amino acid 
molarities of hPPARα and hLXRα in the absence (open circles) and presence (closed circles) 
of 5µM GW-6471.  Each spectrum is composed of an average of ten scans, taken from three 







Supplemental Table 2.  Secondary structures of hPPARα and hLXRα (corrected for 




















DMSO 24.5 ± 0.5 20.5 ± 3.5 12.0 ± 2.0 14.5 ± 0.5 11.5 ± 0.5 16.5 ± 0.5 
Auraptene 26.3 ± 0.3 19.3 ± 1.8 11.3 ± 1.8 13.7 ± 0.9 14.0 ± 2.1 16.3 ± 0.9 
GW 6471 26.3 ± 1.5 22.7 ± 1.9 11.3 ± 1.5 11.7 ± 1.9 13.7 ± 0.7 15.0 ± 0.0 
Asterisks (*) represent significant differences due to presence of ligand as compared with the absence 





































































Supplemental Figure 2. FRET using AF-488hLXRα as the donor and AF-555hRXRα as 
the acceptor.  (A) 25nM AF-488hLXRα titrated against increasing concentrations of 0nM to 
100nM AF-555hRXRα.  The x-axis represents wavelength (nm) and the y-axis depicts 
fluorescence intensity.  Excitation wavelength was set at 488nm and emission scans were 
collected over a range of 500-667nm.  (B) 25nM AF-488hLXRα titrated against increasing 
concentrations of 0nM to 100nM AF-555hRXRα.  The x-axis indicates the concentration of 
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Supplemental Figure 3.  Quantitative analysis of transiently transfected COS-7 cells in 
response to synthetic ligands where ECFP-hPPARα is the central partner receptor.  (A) 
Fluorescence intensity for CFP and YFP in the absence and presence of synthetic ligands.  
The x-axis indicates Kd values for the hPPARα-hLXRα heterodimer, previously determined 
from FRET in the absence and presence of ciprofibrate, fluorobexarotene and T-0901317.  
The y-axis indicates the average corrected total cell fluorescence (CTCF) for both CFP and 
YFP.  (B) Co-localization of hLXRα and hPPARα in COS-7 cell nuclei in the absence and 
present of synthetic ligands.  The x-axis indicates Kd values for the hPPARα-hLXRα 
heterodimer, previously determined from FRET in the absence and presence of ciprofibrate, 
fluorobexarotene and T-0901317.  The y-axis indicates co-localization overlap, R, which is 











































































Supplemental Figure 4.  Quantitative analysis of transiently transfected COS-7 cells in 
response to synthetic ligands where ECFP-hLXRα is the central partner receptor.  (A) 
Fluorescence intensity for CFP and YFP in the absence and presence of synthetic ligands.  
The x-axis indicates Kd values for the hPPARα-hLXRα heterodimer, previously determined 
from FRET in the absence and presence of ciprofibrate, fluorobexarotene and T-0901317.  
The y-axis indicates the average corrected total cell fluorescence (CTCF) for both CFP and 
YFP.  (B) Co-localization of hLXRα and hPPARα in COS-7 cell nuclei in the absence and 
present of synthetic ligands.  The x-axis indicates Kd values for the hPPARα-hLXRα 
heterodimer, previously determined from FRET in the absence and presence of ciprofibrate, 
fluorobexarotene and T-0901317.  The y-axis indicates co-localization overlap R, which is 
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